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Abstract 
 
 S-glutathionylation has been found to control the production of mitochondrial reactive 
oxygen species (ROS), regulated by glutaredoxin-2 (GRX2). GRX2 deficiency is associated with 
heart disease, neurological deficits, and cataracts, which have all been linked to increased ROS 
production. Using GRX2+/- and GRX2-/- mice, we have shown that GRX2 controls the emission of 
superoxide (O2●-) /hydrogen peroxide (H2O2) from liver and cardiac mitochondria in a tissue and 
substrate dependant manner. In cardiac tissue, GRX2+/- and GRX2-/- mitochondria display 
increased O2●-/H2O2 production compared to WT when metabolizing succinate. In liver tissue, 
mitochondria isolated from GRX2-/- mice show a significant decrease in O2●-/H2O2 emission when 
metabolizing pyruvate and 2-oxoglutarate. Our results show that GRX2 plays an important role in 
controlling mitochondrial ROS production in different tissues. Future work into the method of 
ROS control by GRX2 could highlight a method to control ROS production and prevent tissue 
damage from increased ROS. 
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1. Introduction 
1.1. Nutrient metabolism 
 Nutrient metabolism encompasses the many chemical reactions that occur in the body 
which are responsible for converting food into usable energy. Digested food can be broken down 
into three types of macromolecules: carbohydrates, lipids and proteins. These macromolecules can 
undergo catabolism to provide energy for powering cellular processes, or can be used for 
anabolism, in which they are used to build necessary proteins, lipids, nucleic acids or 
carbohydrates. During catabolism, each type of macromolecule is processed through different 
metabolic pathways that ultimately converge on the Krebs cycle in the mitochondria. Exceptions 
include mitochondrial dehydrogenases that can transfer electrons from certain types of carbon 
directly to the ubiquinone (UQ) pool (e.g. electron transferring flavoprotein:quinone 
oxidoreductase, ETF:QOR) Once carbon reaches this point, it’s electrons are converted to reducing 
equivalents that can be used by the electron transport chain (ETC) to form adenosine triphosphate 
(ATP). ATP is the energy currency of the cell, which is required to power the cellular reactions of 
the body.   
1.1.1. Glycolysis 
 Carbohydrates ingested from dietary sources are first broken down into monosaccharide 
units, which most commonly include the hexose sugars glucose, fructose, and galactose, prior to 
absorption via the gut (1). After absorption, these monosaccharides are distributed throughout the 
body for energy metabolism and storage. The use of monosaccharides for energy metabolism 
requires their breakdown in the cytoplasm by glycolysis, a series of ten enzymatic reactions that 
convert one monosaccharide into two molecules of pyruvate. The first five steps of glycolysis are 
labelled as the preparatory phase. In these steps, glucose is broken down into two three carbon 
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sugars. This phase requires the input of energy, two ATP per molecule of glucose, to proceed. The 
first step of glycolysis is catalyzed by hexokinase, which expends ATP to phosphorylate glucose, 
forming membrane impermeable glucose-6-phosphate. (2). The hexokinase isozyme in liver, 
glucokinase, has a lower affinity for glucose which is integral for maintaining blood glucose levels 
(3). The next step converts glucose-6-phosphate to fructose-6-phosphate via phosphoglucose 
isomerase (4). This is also the entry point for phosphorylated fructose into glycolysis. Next, a 
second molecule of ATP in the preparatory phase is used by phosphofructokinase to phosphorylate 
fructose-6-phosphate, producing fructose-1,6-bisphosphate (5). In the two remaining steps, 
fructose-1,6-bisphosphate is cleaved, forming two molecules of glyceraldehyde-3-phosphate (1).  
 The second half of glycolysis is known as the payoff phase. This phase encompasses five 
steps which ultimately end in the production of two pyruvate molecules per glucose. The second 
half is labelled the payoff phase because it produces four ATP and two molecules of reduced 
nicotinamide adenine dinucleotide (NADH) per glucose molecule. The sixth step of glycolysis is 
the oxidation and phosphorylation of the glyceraldehyde-3-phosphate, producing NADH from 
nicotinamide adenine dinucleotide (NAD+) (6). The phosphate on the carbon-1 position of 1,3-
bisphosphoglycerate is then transferred to adenosine diphosphate (ADP) forming ATP by 
phosphoglycerate kinase via a process called substrate level phosphorylation (7). The eighth and 
ninth steps involve an isomerase and enolase reaction which form high energy 
phosphoenolpyruvate (1). The last step of glycolysis encompasses the second substrate level 
phosphorylation of the pathway, forming ATP and producing the end product, pyruvate (8). 
Overall, glycolysis produces a net amount of two ATP and two NADH per molecule of glucose. 
If the cell does not have access to oxygen, it can obtain its energy anaerobically via glycolysis. 
However, aerobic respiration, which is discussed in detail below, produces a much larger sum of 
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ATP per glucose. In theory, aerobic respiration produces 38 ATP per molecule of glucose, but the 
yield is likely closer to 30 ATP in the cell (9). Anaerobic respiration still occurs throughout the 
body, most notably in red blood cells or fast twitch muscle fibers, and involves the re-oxidation of 
NADH through lactic acid fermentation. 
1.1.2. Beta-oxidation of fatty acids 
 Fatty acids that are obtained from the diet or from adipocyte storage can be oxidized to 
transform energy to a useable form. Fatty acids enter the mitochondrial matrix via the acyl-
carnitine/carnitine antiporter (10). Once inside the matrix, fatty acids are systematically stripped 
of electrons through β-oxidation which drives ATP production. Fatty acids are shortened two 
carbons per cycle by removing one acetyl-CoA unit from the terminal carboxyl end of the molecule 
(1). This process is performed in four steps. The first step involves the formation of a double bond 
between the alpha and beta carbon of the fatty acid by acyl-CoA dehydrogenase, reducing flavin 
adenine dinucleotide (FAD) to form a molecule of reduced flavin adenine dinucleotide (FADH2) 
(11). A molecule of water is added to the double bond by the enzyme enoyl-CoA hydratase, 
forming an alcohol group on the beta carbon of the fatty acid (12). In the third step, the alcohol is 
then dehydrogenated to a ketone by the enzyme -hydroxyacyl-CoA dehydrogenase (1). The 
electrons from this step are used to form NADH. The final step of beta-oxidation involves the 
liberation of a two-carbon unit that combines with coenzyme A (CoA) to form acetyl-CoA, 
facilitated by the enzyme thiolase (1). These four steps are repeated until the fatty acid has been 
completely broken down into acetyl-CoA. If the fatty acid is unsaturated, an extra step is required 
for isomerization into a trans configuration double bond, which can then proceed with beta-
oxidation (1). Overall, each pass of beta-oxidation produces one molecule of acetyl-CoA, FADH2 
and NADH. Acetyl-CoA can have many fates within the body. Acetyl-CoA produced from 
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oxidation of fatty acids in the mitochondria is mostly used to generate ATP via its entry into the 
Krebs cycle. However, it can also be used to make ketone bodies, a valuable source of energy for 
various tissues.  
1.1.3. Protein oxidation 
 Unlike carbohydrates and fatty acids, amino acids obtained from the digestion of proteins 
cannot be stored in the body for later use. They are either used to build proteins or they are oxidized 
for energy (1). Protein from the diet is hydrolysed into free amino acids in the small intestine and 
then transported to the liver via the blood. Once they reach the liver, most amino acids undergo 
deamination by a transaminase enzyme, transferring the amino group to 2-oxoglutarate, forming 
glutamate and leaving behind an alpha-keto acid (1). Glutamate can then be transferred to the 
mitochondria and deaminated by glutamate dehydrogenase to release an ammonium ion (NH4+) 
into the urea cycle, leaving behind 2-oxoglutarate which can re-enter the Krebs cycle (13). 
Glutamate can also transfer its amino group to oxaloacetate by aspartate aminotransferase to form 
2-oxoglutarate and aspartate, which can directly enter the urea cycle (14).  
 Amino acids degraded in extrahepatic tissues produce NH4+, which is combined with 
glutamate by glutamate synthetase to form glutamine (15, 16) that can be transported to the liver. 
Once glutamine has reached the liver mitochondria, it can be cleaved back to glutamate by 
glutaminase, releasing NH4+ to the urea cycle (16). NH4+ can also be transported to the liver by the 
glucose-alanine cycle. Glutamate present in the tissue can transfer the NH4+ group to pyruvate via 
the enzyme alanine aminotransferase to form alanine which can travel through the blood to the 
liver (17). In the liver, alanine is then deaminated back to pyruvate, transferring NH4+ to 2-
oxoglutarate to form glutamate (17).  
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 Any nitrogen which is not used by the body for protein synthesis must be excreted. This is 
performed through the urea cycle, which consists of five enzymatically mediated reactions that 
convert hepatic ammonia to urea so that it may be excreted by the kidneys (1). The urea cycle 
occurs in the mitochondria and cytosol of liver cells, and ultimately results in the production of 
urea. To enter the urea cycle, free NH4+ is cleaved from glutamine and glutamate in the 
mitochondria. NH4+ must first combine with bicarbonate and two molecules of ATP to form 
carbamoyl phosphate, driven by the enzyme carbamoyl phosphate synthetase 1 (18). Carbamoyl 
phosphate can then enter the urea cycle. The urea cycle results in the production of fumarate, which 
can re-enter the Krebs cycle, as well as urea, which enters the blood stream to be filtered out and 
excreted by the kidneys.  
 Once the amino group has been separated from the amino acids, the carbon skeletons are 
now free to be oxidized for energy production. There are several different amino acid degradation 
pathways, depending on the structure of the amino acid carbon skeleton. Some amino acids are 
known as ketogenic amino acids. This means that they can only be converted to acetyl-CoA and 
therefore can either enter the Krebs cycle and be oxidized into carbon dioxide (CO2) or they can 
be used to produce ketone bodies to feed the body during times of negative energy balance (1). 
Other amino acids are termed as gluconeogenic, meaning they can be converted back to glucose 
via the process of gluconeogenesis. These amino acids are converted to intermediates such as 
pyruvate, 2-oxoglutarate, succinyl-CoA, fumarate or oxaloacetate (1). These products are all 
intermediates of the Krebs cycle and can therefore enter at different points to be oxidized for fuel. 
Five amino acids exist that are classified as both gluconeogenic and ketogenic (1), and therefore 
can have different fates, depending on metabolic needs.  
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1.1.4. The Krebs cycle 
 The catabolism pathways of carbohydrates, fats, and amino acids ultimately form the 
common intermediates, acetyl-CoA, oxaloacetate, and 2-oxoglutarate, which enter the Krebs cycle 
for further oxidation. The Krebs cycle consists of eight enzymatically mediated reactions which 
function to oxidize carbon skeletons, forming CO2 as a by-product, and producing reduced NADH 
and FADH2, which can be further oxidized in the ETC to produce ATP. A diagram of the Krebs 
cycle can be found in Figure 1.1. The Krebs cycle is in the mitochondrial matrix and is required to 
produce fuel as dictated by the needs of the body.   
 For carbohydrates to enter the Krebs cycle, they must first undergo glycolysis, where they 
are used to produce pyruvate. Pyruvate is imported to the mitochondrial matrix by the symporter 
pyruvate translocase, which is powered by the symport of protons. Once inside the matrix, 
pyruvate is converted to acetyl-CoA by the pyruvate dehydrogenase complex (PDH). PDH is the 
gateway for carbohydrate oxidation in mitochondria since it is required to convert pyruvate to 
acetyl-CoA prior to its entry into the Krebs cycle. PDH is composed of three subunits, the first 
being pyruvate decarboxylase (E1 subunit), which facilitates the decarboxylation and transfer of 
pyruvate to thiamine pyrophosphate (TPP) (19). In the E2 subunit, dihydrolipoyl tranacetylase, the 
acetyl group and two electrons are transferred to the reduced lipoamide group, forming acyl 
lipoyllysine (19).  A transesterification reaction occurs next, in which CoA replaces the lipoamide 
on the acetyl group, forming acetyl-CoA and leaving behind reduced lipoyllysine (19). The E3 
subunit is termed dihydrolipoyl dehydrogenase and functions to re-oxidize the lipoyllysine group, 
passing the electrons on to a flavin group to form FADH2 (19). The reduced FADH2 then passes a 
hydride ion to NAD+ to form NADH (19). The enzyme is now returned to its original configuration 
and can proceed with further reactions. This can be visualized in Figure 1.2. Acetyl-CoA can now  
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Figure 1.1: The Krebs cycle 
This diagram shows the steps of the Krebs cycle, as well as its entry points. Acetyl-CoA is oxidized 
to CO2, producing three NADH, one FADH2, and one GTP/ATP. 
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Figure 1.2: The pyruvate dehydrogenase complex 
This diagram shows the overall reaction of PDH. (1) The decarboxylation of pyruvate by pyruvate 
decarboxylase, producing CO2 and passing the acetyl group to TPP. (2) The acyl group is passed 
from TPP to lipoyllysine. (3) Acyl lipoyllysine reacts with CoA to release acetyl-CoA and produce 
reduced lipoyllysine. (4) The oxidation of lipoyllysine by FAD, producing FADH2. (5) FADH2 is 
re-oxidized by NAD+. 
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proceed directly to the Krebs cycle. PDH is an important regulatory enzyme of the Krebs cycle. It 
is allosterically inhibited by its own product, acetyl-CoA, as well as by high ratios of ATP/ADP 
and NADH/NAD+ and long chain fatty acids (1). PDH can also be covalently regulated by 
phosphorylation of a serine residue on the E1 subunit, mediated by pyruvate dehydrogenase kinase 
and pyruvate dehydrogenase phosphorylase (19). 
 Fatty acids, as well as ketogenic amino acids, also enter the Krebs cycle as acetyl-CoA. 
Acetyl-CoA combines with oxaloacetate in a claisen condensation reaction to form citrate, a 
reaction catalyzed by citrate synthase, releasing CoA (20). Aconitase then catalyzes the 
isomerization of citrate to isocitrate through a cis-aconitate intermediate (21). The conversion of 
isocitrate to 2-oxoglutarate via isocitrate dehydrogenase releases CO2 and produces the first 
molecule of NADH in the cycle (1). 2-Oxoglutarate is a major entry point for amino acids into the 
Krebs cycle, specifically via the metabolism of glutamate by glutamate dehydrogenase. The next 
step of the cycle involves the oxidation of 2-oxoglutarate by the 2-oxoglutarate dehydrogenase 
complex (OGDH), producing succinyl-CoA, CO2 and NADH (22). In terms of basic structure, 
OGDH is highly homologous to PDH, utilizing a similar mechanism for the oxidation of 2-
oxoglutarate and the formation of NADH. The E1 subunit, 2-oxoglutarate decarboxylase, removes 
CO2 from 2-oxoglutarate and attaches the succinyl group to the TPP cofactor (22). Dihydrolipoyl 
succinyltransferase, the E2 subunit, catalyzes the transfer of the succinyl group to the oxidized 
lipoamide group, which is then transferred to CoA, releasing succinyl-CoA (22). The E3 subunit, 
dihydrolipoyl dehydrogenase, is the same enzyme present in PDH, and functions in the same 
manner, to pass electrons from the reduced lipoamide to the flavin group and then to NAD+, 
producing NADH and returning the complex to its original conformation (22). OGDH, like PDH, 
is also an important regulatory step of the Krebs cycle. The enzyme complex is allosterically 
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inhibited by high ratios of ATP/ADP, NADH/NAD+ and increased concentrations of succinyl-
CoA (1).  
 The sixth step of the Krebs cycle is catalyzed by succinyl-CoA synthetase, forming 
succinate from succinyl-CoA, with the substrate-level phosphorylation of ADP or guanine 
diphosphate (GDP) to ATP or guanine triphosphate (GTP), respectively (23). The next enzyme, 
succinate dehydrogenase, is both complex II of the ETC as well as the only membrane bound 
Krebs cycle enzyme, which catalyzes the conversion of succinate to fumarate and the production 
of FADH2 (1). Fumarate then undergoes a hydration reaction to malate, catalyzed by fumarase (1). 
The final step of the Krebs cycle is the dehydrogenation of malate to oxaloacetate by malate 
dehydrogenase, producing the final NADH of the cycle (24). Overall, each molecule of acetyl-
CoA that enters the Krebs cycle is oxidized to two molecules of CO2 and produces three molecules 
of NADH, one FADH2 and one substrate level phosphorylated GTP/ATP. The reducing 
equivalents generated in the Krebs cycle are oxidized by enzymes in the ETC to power to the 
process of oxidative phosphorylation.  
1.1.5. Oxidative phosphorylation 
 Oxidative phosphorylation is the method by which almost all aerobic organisms harness 
the energy derived from the metabolism of nutrients and use it to produce the universal energy 
currency, ATP.  Oxidative phosphorylation is performed by a series of enzymes collectively called 
the respiratory complexes (also called the electron transport chain or ETC), which consists of 
enzyme complexes I-V, located in the mitochondrial inner membrane (Figure 1.3). Electron donors 
produced during the Krebs cycle and other metabolic pathways, donate their electrons to 
complexes in the ETC, which shuttle them along the chain to the terminal electron accepter, 
molecular oxygen (O2), forming water (H2O) (note that the full reduction of O2 to H2O requires 4  
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Figure 1.3: The electron transport chain  
The flow of electrons through the ETC from NADH and succinate, to the terminal electron 
acceptor, O2. During this process protons are pumped from the mitochondrial matrix to the 
intermembrane space. 
  
 12 
electrons in total). The passage of electrons through the chain is coupled to the pumping of protons 
from inside the mitochondrial matrix to the intermembrane space. This process forms the proton 
gradient, which can then be harnessed for the formation of ATP by ATP synthase.  
 The first enzyme complex of the ETC is NADH:ubiquinone oxidoreductase, known more 
commonly as complex I, which catalyzes the transfer of electrons from NADH to the coenzyme 
UQ. Complex I is the largest ETC complex, containing 45 subunits, a flavin mononucleotide 
(FMN), and seven iron-sulfur (Fe-S) clusters (25). The complex is “L” shaped, with one arm 
anchored in the mitochondrial inner membrane, and the other hydrophilic arm located in the 
matrix. The hydrophilic section of the complex contains the binding site for NADH. Two electrons 
are liberated from the oxidation of NADH and are transferred to FMN, then through the Fe-S 
clusters to UQ, reducing it to ubiquinol (UQH2) (26). During this process four protons are pumped 
from the matrix to the intermembrane space by complex I. UQH2 then carries the electrons down 
the chain to complex III (26). Complex I can exist in two different conformations: the catalytically 
active “A” form, as well as the inactive “D” form, which can occur during pathological conditions 
such as ischemia (27).  
 Complex II of the ETC, succinate-ubiquinone oxidoreductase, is also known as succinate 
dehydrogenase (SDH) of the Krebs cycle. Its function is to oxidize succinate and transfer the 
electrons through the complex to UQ. Mammalian complex II is a ~120 KDa protein complex (28) 
composed of four subunits: subunit A and B are hydrophilic subunits that are present in the 
mitochondrial matrix, while the hydrophobic subunits C and D are anchored in the membrane (29). 
Subunit A contains the binding site for succinate, as well as a bound FAD. Electrons are passed 
from succinate to FAD, producing FADH2 (30). Subunit B contains three Fe-S clusters, which 
tunnel electrons from FADH2 to the UQ binding site, located in subunits C and D (30). UQH2 is 
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produced which then transports electrons to complex III. Subunits C and D also contain a b-type 
heme that does not seem to be involved in the transfer of electrons, but may be involved in 
preventing their escape from the complex (29).  
 Electrons donated to UQ by complexes I and II are transported to complex III of the ETC, 
more formally known as ubiquinone:cytochrome c oxidoreductase. The function of this complex 
is to facilitate the transfer of electrons from UQH2 to the heme protein cytochrome c, while 
pumping four protons from the matrix to the intermembrane space. The structure of complex III is 
a homodimer, with each monomer containing 11 subunits (31). Three of these subunits are known 
to be involved in the passage of electrons: cytochrome b, which contains two b-type heme groups 
(bL and bH), the Rieske iron-sulfur protein, which contains two Fe-S centers, and cytochrome c1, 
which contains a c-type heme group (c1) (31). To pass only one electron from UQH2 to cytochrome 
c, complex III uses the Q cycle to recycle a lone electron back to UQ. The overall reaction involves 
the oxidation of two UQH2 to UQ, the reduction of one UQ to UQH2, the reduction of two 
cytochrome c molecules, the uptake of two protons from the matrix and the release of four protons 
into the intermembrane space (32). In the first round of the Q cycle, UQH2 binds to the Q0 site of 
complex III while UQ binds to the Qi site. UQH2 is oxidized, and its two protons are released to 
the intermembrane space (32). One electron is passed to the Fe-S center in the Rieske iron-sulfur 
cluster protein, then cytochrome c1 and ultimately to cytochrome c, which can then bring the 
electron further down the ETC (32). The other electron is passed from the bL to the bH heme and 
then to the bound UQ, forming a ubisemiquinone (32). To fully reduce the ubisemiquinone, a 
second round of the Q cycle is performed by binding another UQH2 and transferring one electron 
to the heme group of cytochrome c, releasing two more protons into the intermembrane space, and 
transferring the second electron to the ubisemiquinone, which also picks up two protons from the 
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matrix to become UQH2 (32). The Q cycle explains how complex III can accommodate the transfer 
of electrons from the two-electron carrier, UQH2, to the one electron carrier, cytochrome c.  
 Once cytochrome c has obtained an electron from complex III, it passes that electron on to 
the fourth complex of the ETC, complex IV. The function of complex IV, also known as 
cytochrome c oxidase, is to pass electrons from cytochrome c to the final electron acceptor of the 
ETC, O2. Complex IV is composed of 14 subunits (33), with three critical ones that are known to 
be involved in electron transfer. They include: subunit I, which contains the heme groups a and a3 
and a copper ion, Cu3, which complexes with a3 to form the a3:Cu3 binuclear center, subunit II, 
which contains two copper ions complexed with two cysteine residues forming the binuclear center 
CuA, and subunit III (1). Electron transfer begins when two reduced cytochrome c molecules bind 
and donate one electron each to subunit II, which are transferred through the CuA center to heme 
a. Heme a transfers the electrons to the a3:Cu3 center (34). At this point, O2 binds to heme a3, and 
is reduced by the two electrons to O22- (34). The delivery of two more electrons through the 
pathway, and the addition of four protons from the matrix, forms two molecules of H2O. During 
this process four protons are transported into the intermembrane space (35).  
 One of the most notable aspects of the ETC is that electron movement from NADH or 
succinate down to the end of the chain to O2 is an energetically favorable process.  The energy 
obtained from the favorable “downhill” transfer is conserved as a transmembrane electrochemical 
gradient of protons which is formed by complexes I, III, and IV. It is important to note that complex 
II does not pump protons into the intermembrane space since it is not an integral membrane protein. 
In addition, the net Gibbs free energy change for electron transfer from succinate to UQ is ~0 
KJ/mol. This gradient is known as the proton motive force (PMF). The PMF has two components: 
chemical energy due to the chemical gradient from the concentration difference of H+ between the 
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matrix and the intermembrane space, and electrical potential energy due to the charge separation 
from the transfer of a positive ion across the membrane, leaving behind a more negatively charged 
matrix. For every NADH oxidized by the ETC, ten protons are transferred to the intermembrane 
space, and for every succinate molecule oxidized, six protons are transferred (since complex II 
does not translocate protons). The chemiosmotic model, proposed by Peter Mitchell, states that the 
energy stored in the PMF is used to power the production of ATP (36). This is achieved by the 
flow of protons down their electrochemical gradient through a channel in ATP synthase (37). The 
oxidation of substrates is therefore tied to the phosphorylation of ADP, hence the term oxidative 
phosphorylation. If the PMF is disrupted, then production of ATP cannot occur. This is evident 
when the PMF is uncoupled from ATP synthesis with proton ionophores or by mitochondrial 
uncoupling proteins. Proton ionophores, such as carbonylcyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), are weak acids that are protonated in the 
intermembrane space allowing for diffusion into the matrix where a proton is released, dissipating 
the PMF (37). Uncoupling proteins are regulated proton channels located in the mitochondrial 
membrane that can also allow protons to diffuse down their gradient (38). When uncoupled, 
mitochondria can still oxidize substrates, but ATP production is diminished since uncoupling 
proteins return protons to the matrix, by-passing ATP synthase (38). Along with energizing the 
formation of ATP, the PMF is also used to transport vital substrates in and out of the mitochondrial 
matrix. The adenine nucleotide transporter transports ADP3- into the matrix in exchange for ATP4-
, which is energetically favourable due to the negative charge of the matrix (39). Phosphate 
translocase also transports the symport of a phosphate group and a proton down the gradient into 
the matrix. Other various nutrient carriers, like the pyruvate carrier, also rely on the PMF to drive 
solute uptake (40). 
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 ATP synthase, also known as complex V, is a large multi-subunit protein located in the 
mitochondrial inner membrane. The overall function of ATP synthase is to catalyze the 
phosphorylation of ADP to ATP, which is powered by the passage of protons down their 
electrochemical gradient through a channel in the enzyme. ATP synthase is composed of two 
functional domains: The F0 domain, which is embedded in the mitochondrial inner membrane and 
contains the channel through which protons travel, and the F1 domain, which is peripheral to the 
inner membrane on the matrix side, and contains the catalytic active sites (41). The F1 domain 
contains five different subunits: , , , , and , with the composition 33 (41). The three  
and  subunits alternate in a circular structure, surrounding a  shaft which associates with one of 
the  subunits. Although the  subunits are identical in composition, they differ in conformation 
due to their association with the  subunit. At all times, the three  subunits are in three different 
conformations: -empty, which contains no substrates, -ADP, which binds ADP and phosphate 
(P), and -ATP, which contains the recently formed ATP (42). The movement of protons down 
the F0 section powers the rotation of the  subunit of the F1 section, a process known as rotational 
catalysis (41). When ADP and P bind to the -ADP site, the conformation of the site changes to 
-ATP, tightly binding the two substrates and bringing them close enough to undergo 
phosphorylation. Once ATP is formed, the subunit changes to the -empty conformation, which 
releases the newly formed ATP due to a low affinity (42). Passage of the protons through the F0 
domain causes the rotation of the  subunit by 120, which allows it to associate with the next  
subunit, changing its conformation (42). The  subunits are held in place during the rotation by 
the  subunit of F1 (1). The interaction between the three  subunits dictates that if one -subunit 
is in the -ADP form, its neighbours must be in the -ATP and the -empty forms (1). One 
complete rotation of the  subunits allows the three  subunits to rotate through all three 
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conformations, catalyzing the production of three ATP molecules per full turn (1). These ATP 
molecules are then transferred out of the matrix to be used to power cellular processes.  
1.2. Reactive oxygen species in mitochondria 
 Reactive oxygen species (ROS) are chemically reactive molecules produced by the 
incomplete reduction of molecular oxygen. The molecular structure of oxygen includes two 
unpaired electrons in its outer most anti-bonding orbitals, meaning that oxygen can only accept 
one electron at a time (43). Therefore, the reduction of O2 to H2O results in the formation of several 
oxygen radical intermediates, namely, superoxide (O2•-), hydrogen peroxide (H2O2) and hydroxyl 
radical (OH•). O2•- and H2O2 are the two proximal ROS produced by mitochondria (44). Of all the 
oxygen consumed by the body for oxidative phosphorylation, it is estimated that approximately 
0.02-0.2% is converted to O2•- (45, 46). H2O2 is a more stable form of ROS which, unlike O2•-, is 
able to diffuse through membranes via aquaporin (47). Excess production of ROS is known to 
cause oxidative damage in cells, and has been associated with a wide array of diseases including 
cardiovascular, inflammatory, and degenerative diseases, as well as cancer (48). O2•- can cause 
enzyme inactivation by disassembling Fe-S clusters (49), while H2O2 disables proteins by 
irreversibly oxidizing cysteine residues (50). Even more damage can occur when O2•- and H2O2 
interact with transition metal ions in the body, most notably free iron or copper, initiating Haber-
Weiss and Fenton reactions which yields OH• (51). OH• is a very reactive molecule that can 
oxidize nucleotides, lipids, and amino acids, resulting in DNA, membrane, or protein damage 
culminating with cellular dysfunction and death.  
 Once thought to be unfortunate by-product of metabolism, ROS are now regarded as 
important secondary signalling molecules involved in modulating different cell functions. H2O2 
has been found to affect enzyme activity by reversibly oxidizing thiol groups to sulfenic acid 
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(SOH) (52). This is referred to as “redox signaling” where cysteine switches are reversibly 
oxidized in response to fluctuations in the surrounding cellular redox environment. In fact, it is 
hypothesized that cysteine switches serve as a critical interface required to modulate cellular 
responses at the genomic, proteomic, and metabolomic levels in response to alterations in the 
surrounding cellular environment. For instance, H2O2 is implicated in stress signaling (Nrf2 
activation (53), apoptosis (54)), T-cell activation (55), adipocyte differentiation (56), 
steroidogenesis (57), and insulin resistance and release (58). 
 ROS is currently known to have at least eleven sites of production within the mitochondria 
(Figure 1.4) (59). These ROS forming sites include respiratory complexes and dehydrogenases 
that are involved in substrate oxidation and the delivery of free electrons to O2 in the respiratory 
chain. They include complexes I and III of the ETC, as well as 2-oxoacid dehydrogenase 
complexes and dehydrogenases that deliver electrons to UQ, such as complex II (59). Seven of 
these sites produce ROS from a flavin group which is associated with the unique radical chemistry 
of FAD and FMN groups in different respiratory complexes and dehydrogenases. The other five 
sites produce ROS from a UQ/UQH2 binding site through the formation of ubisemiquinone 
radicals in different membrane bound dehydrogenases and respiratory complexes. Nine of the sites 
produce O2•- and H2O2 into the mitochondrial matrix, while two sites, complex III and glycerol-3-
phosphate dehydrogenase, can produce ROS directly into the mitochondrial intermembrane space 
(59). Most work in discerning which enzymes serve as high capacity sites in mitochondria has 
been carried out in skeletal muscle mitochondria (59). It was found that complex III serves as the 
highest capacity site overall (59). Intriguingly, the 2-oxoacid dehydrogenase complexes, OGDH 
and PDH, were found to generate ~8x and ~4x more ROS than complex I during thr oxidation of 
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Figure 1.4: Sites of ROS production in mitochondria 
The known sites of ROS production in the mitochondria. They are divided into the NADH/NAD+ 
isopotential sites and the QH2/Q isopotential sites.  
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Kreb’s cycle linked substrates (59). In addition, complex II was found to be an important source 
as well as complex I, but only under conditions of electron back flow from succinate (60). Our 
group recently started examining which enzymes serve as high capacity ROS production sites in 
liver and cardiac tissue mitochondria. It was found that complex III produces ~45% of the 
mitochondrial ROS in liver tissue and OGDH yields ~35% while sites like PDH and complex I 
account for the rest (61, 62). By contrast, complex I and III serve as the highest capacity sites in 
cardiac tissue, regardless of what substrate is being oxidized (Krebs cycle linked substrates or 
carbon that donates electrons directly to the respiratory chain) (63).  
 Levels of ROS in the mitochondria are closely regulated by a few different mechanisms. 
O2•- produced in the mitochondria is quickly dismutated to H2O2 by the enzyme superoxide 
dismutase (SOD). The kinetics for the dismutation of O2•- have been estimated to approach a rate 
constant of 2.3 x 109 M-1 s-1, meaning that its concentration is very low, in the picomolar (pM) 
range (43). Within the mitochondrial matrix, O2•- is dismutated by manganese SOD (MnSOD), 
while the intermembrane space relies on copper SOD (CuSOD) and zinc SOD (ZnSOD) (64). 
There are many different mechanisms by which mitochondria H2O2 can be degraded into less 
harmful chemicals. The three main systems include catalase, which degrades H2O2 into H2O and 
O2, and the glutathione (GSH) and thioredoxin (PRX) systems, which use their own mechanisms 
to quench H2O2 (62). Typically, the GSH and PRX systems are thought to the be major methods 
of clearance in mitochondria. However, catalase has recently been shown to play an important role 
in eliminating H2O2 (62). 
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1.3. Mitochondrial hydrogen peroxide clearing systems  
1.3.1. Glutathione antioxidant system 
 GSH is a tripeptide molecule made up of glutamate, cysteine, and glycine. The synthesis 
of GSH occurs in the cytosol and is mediated by -glutamylcysteine synthetase, which catalyzes 
the addition of glutamate and cysteine, and then glutathione synthase, which adds glycine (65). 
GSH is transported from the cytosol into the mitochondria through a still unknown transporter 
(66). The concentration of GSH in the matrix of mitochondria is 1-10 mM (varies between different 
tissues, with liver containing the most and muscle having the least), while the oxidized form, 
glutathione disulfide (GSSG), occurs at 0.01-0.1 mM. The ratio of GSH:GSSG in mitochondria is 
typically kept at approximately 100:1, but can decrease during times of oxidative stress (67). This 
ratio is maintained by the activity of glutathione reductase (GR), which reduces GSSG to two 
molecules of GSH, using the cofactor nicotinamide adenine dinucleotide phosphate (NADPH).  
One of the major functions of the GSH system is the degradation of H2O2 to H2O by the action of 
glutathione peroxidase (GPx). The reduction of H2O2 to two molecules of H2O also causes the 
formation of GSSG from two molecules of GSH. GSSG is then converted back to GSH by the 
activity of GR and NADPH (Figure 1.5) (68). There exist different isozymes of GPx which 
catalyze the reduction of different peroxides. The above reaction is catalyzed by the mitochondrial 
matrix soluble GPx1 (68). GPx4 is located on the matrix side of the mitochondrial inner membrane 
and functions to reduce phospholipid hydroperoxides to alcohols, slowing the propagation of lipid 
peroxidation within the membrane (68).  
 The GSH system is also involved in the detoxification of xenobiotic substrates and products 
of endogenous oxidative damage such as , -unsaturated aldehydes, epoxides, and alkyl 
hydroperoxides (68). These reactions are catalyzed by glutathione-s-transferase (GST), which  
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Figure 1.5: Catalytic cycle and functions of the glutathione system 
This diagram illustrates the different functions of the glutathione system. 
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transfers GSH to the targeted substrates, producing a GSH thioester-xenobiotic conjugate which 
is effluxed from the mitochondria (68).  
 The third known function of glutathione is redox signaling through the addition of GSH to 
protein cysteine thiols in a mechanism called S-glutathionylation. Reversible S-glutathionylation  
is catalyzed by the enzyme glutaredoxin (GRX) (69). In the mitochondrial matrix and nucleus of 
the cell, glutaredoxin-2 (GRX2) catalyzes the addition and removal of GSH (note though that 
GRX2 has only been found to occur in the lumen of the nucleus in cancer cells) (70), while 
glutaredoxin-1 (GRX1) catalyzes this reaction in the cytosol and intermembrane space of 
mitochondria. S-glutathionylation of enzymes within the Krebs cycle and the ETC is a vital 
mechanism for control of ROS production, which will be discussed further in section 1.5.  
1.3.2. Peroxiredoxin antioxidant system 
 To prevent toxic concentrations of H2O2 from accumulating within the cell, mitochondria 
contain a few different antioxidant systems, one of them being the peroxiredoxin system. 
Peroxiredoxins (PRX) are a family of thiol peroxidases which quench cellular H2O2. The catalytic 
cycle begins when H2O2 reacts with a cysteine thiol residue called the “peroxidatic cysteine”, 
forming SOH (71). Mitochondrial PRX isoforms include PRX3 and PRX5 (71). Mitochondrial 
PRX3 is a typical 2-Cys PRX, meaning it is a homodimer oriented in a head to tail fashion, using 
cysteine thiol residues from both subunits for degradation of H2O2 (71). Reduction of one H2O2 
molecule to H2O causes both cysteine thiols on PRX3 to become oxidized to SOH (71). The two 
PRX3 units then condense to form an oxidized dimer with two intermolecular disulfide bonds, 
releasing two molecules of H2O. The oxidized PRX3 is reduced by thioredoxin2 (TRX2), which 
in turn is reduced by thioredoxin reductase (TR) using the power of NADPH (71). PRX3 can be 
hyperoxidized to sulfinic acid (SO2H) in the presence of excess H2O2, causing it to be inactivated.  
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Hyperoxidized PRX3 can be reduced back to its active state by sulfiredoxin, but the reaction 
proceeds very slowly with a rate constant of k=0.18 min-1 (71). This mechanism of inactivation is 
thought to allow H2O2 to accumulate enough to exert signalling effects (64). This mechanism can 
be viewed in Figure 1.6. 
 Mitochondrial PRX5 proceeds via a different mechanism. It is an atypical 2-Cys PRX that 
exists as a monomer and forms an intramolecular disulfide bond when oxidized to SOH by H2O2. 
PRX5 is then reduced by to its active state via the same pathway as PRX3. PRX3 is a more 
effective H2O2 scavenger than PRX5, with a rate constant that is about two orders of magnitude 
larger (71). However, PRX5 has been found to be a more effective scavenger of organic 
hydroperoxides, indicating that it may be more suited for repairing oxidative damage (72). It has 
been estimated that the bulk of mitochondrially produced H2O2 is degraded by the PRX antioxidant 
system, with around 90% reacting with PRX3. However, mitochondria would not be able to keep 
ROS levels in check with PRX only, as depletion of GSH or knockdown of GPx1 has been shown 
to cause increases in cell susceptibility to oxidative stress (73, 74).  
1.4. Control over ROS production 
 The production of O2•-/H2O2 by mitochondria depends on several factors including the 
concentration of the electron donating site, the redox state of the electron donor, and access to O2. 
While the degradation of O2•-/H2O2 by antioxidant systems is an important method of ROS control, 
there exists other mechanisms by which mitochondria can exert control over the production of 
ROS from different sites. Three of the most important methods of control include: changes in 
proton leak, the formation of supercomplexes and the use of redox signals.  
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Figure 1.6: Peroxiredoxin catalytic cycle 
This diagram illustrates the catalytic cycle of PRX3, showing its oxidation to a dimer, and then 
how it is reduced back to its active state by TRX2. 
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1.4.1. Proton leak 
 Proton leak is the return of protons to the mitochondrial matrix independently of ATP 
synthase. This causes depletion of the PMF used to power the phosphorylation of ADP. There are 
two types of proton leak that occur in mitochondria. The first is basal leak, which is minor, 
unregulated leak through the lipid bilayer as well as through the membrane protein adenine 
nucleotide translocase (ANT) (75). The second is called inducible leak and is regulated by specific 
mitochondrial inner membrane proteins such as uncoupling proteins (UCP) 1-3 (75). Notably, this 
may seem energetically wasteful but is likely the most studied mechanism for the prevention of 
mitochondrial ROS formation. 
 The production of ROS has been shown to be highly sensitive to changes in proton leak 
and to have a non-ohmic relationship with the PMF, meaning that small increases in the membrane 
potential can induce exponential increases in ROS production (54, 76). Induction of proton leaks 
has been shown to decrease the production of ROS from the ETC by preventing the over-reduction 
of electron donating sites for ROS formation (77). Indeed, loss of proton uncouplers like UCP2 or 
UCP3 is associated with the induction of oxidative stress and the overproduction of ROS by 
mitochondria (78, 79). Moreover, products of increased oxidative stress, such as 4-hydroxynonenal 
(4-HNE), have been found to induce proton leakage through UCPs, decreasing ROS production. 
A mechanism has been proposed which constitutes a negative feedback loop: increased 
concentration of ROS in the mitochondria leads to increased proton leakage, slowing down rate of 
ROS production (79).  
 UCP2 and UCP3 are thought to be major regulators of proton leakage in response to ROS. 
UCP2 is ubiquitously expressed throughout the body, while UCP3 is found mostly in skeletal 
muscle, cardiac muscle, and to a small extent in brown adipose tissue. Inhibition of UCP2 has been 
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found to cause increases in H2O2, while overexpression diminishes ROS production and protects 
from oxidative damage (80, 81). Similar trends have been found for UCP3. UCP3 knockout mice 
show increased levels of ROS and oxidative stress (82), while overexpression has been found to 
lower mitochondrial O2•-/H2O2 emission (83). Although numerous studies have shown that UCP2 
and 3 play a role in decreasing oxidative stress, the exact mechanism is still up for debate. There 
have also been studies that provide evidence in contrary of their control of ROS production via 
changes in proton leak. Some studies have given evidence of alternate functions of UCP2 and 3 
(84, 85), while other studies have concluded that changes in the PMF do not cause any effect on 
ROS production (86).     
1.4.2. Supercomplexes 
The complexes of the ETC were originally assumed to exist individually and be randomly 
distributed in the mitochondrial inner membrane. However, recent evidence has indicated that this 
is not the case. The theory of supercomplexes, also called respirasomes, was proposed in 2000 to 
explain why some complexes migrate together during polyacrylamide gel electrophoresis (87). 
The isolated respirasomes were found to consist of complexes I, III and IV (87). Later, it was 
discovered that isolated respirasomes were active and able to reduce O2 in the presence of NADH 
(88). Complex I was found to form supercomplexes with other ETC complexes in many different 
combinations (88). The total evidence gathered about the nature of the ETC complexes cannot be 
completely explained by the supercomplex model, or by the free complex model and so, a model 
of complex plasticity has been proposed. The plasticity model postulates that complexes can exist 
as free units or as supercomplexes, depending on the nature of the environment (89, 90).  
 Supercomplex assembly has also emerged as a method for the control of ROS production. 
The loss of supercomplex assembly, and therefore the increase of free complex I, has been shown 
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to increase ROS production from the complex (91). Free complex I allows the FMN containing 
subunit to be more exposed, possibly increasing its chances of reacting with O2 to form ROS (92). 
Another possibility is that free complex I experiences increased over-reduction of the FMN 
containing subunit due to decreased electron transfer to complex III. Further research is required 
to validate either of these hypotheses. However, it is possible that mitochondrial ROS levels may 
be controlled by facilitating the assembly of complex I into supercomplexes with other respiratory 
complexes.   
1.4.3. Redox signals  
1.4.3.1. Sulfenylation 
 Protein cysteine thiol residues in the mitochondria have been studied extensively as targets 
for redox signalling and control and can undergo many reactions (Figure 1.7). The oxidation of a 
thiol group to SOH by H2O2 is termed sulfenylation and its significance as a redox signal has been 
reviewed considerably. It has been suggested that sulfenylation could be a negative feedback 
mechanism used by H2O2 to limit ROS production from certain enzymes. The caveat to this 
hypothesis is that few enzymes in the mitochondria have been found to be sulfenylated. Also, 
sulfenylation has not been found to fit the conditions for an effective post-translational 
modification. For a redox signal to be efficient, it should meet certain criteria, much like other 
well-known modifications like phosphorylation. Redox modifications must be specific, reversible, 
rapid, and fulfill some physiological role (93). Sulfenylation of thiols is a very slow reaction (rate 
constant: K=5-500 M-1s-1) and the reactions are not catalyzed by any known enzyme (93). Protein 
sulfonates are also strong nucleophiles and are thus very unstable and can form a number of 
different adducts (93). Sulfenic acids can be further oxidized by H2O2 to SO2H, and even further 
to the irreversible sulfonic acid (SO3H). Sulfenic and sulfinic acids can be reverted back to thiol 
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different adducts (93). Sulfenic acids can be further oxidized by H2O2 to SO2H, and even further 
to the irreversible sulfonic acid (SO3H). Sulfenic and sulfinic acids can be reverted back to thiol  
 
 
 
 
 
Figure 1.7: Reactivity of thiols 
The many possible fates of free thiols in the mitochondria are illustrated including: [1] sulfonic 
acid, [2] sulfonamides, [3] disulfides, [4] S-glutathionylated thiols and [5] thiosulfinate. 
 
 
 
 
 
 
 
 
 30 
groups via the action of sulfiredoxin (94), however this is thought to be a defense mechanism to 
prevent the irreversible deactivation of enzymes by oxidation to SO3H. It has been proposed that 
sulfenylation may serve as a means to promote the formation of disulfide or sulfonamide bonds 
during protein folding (95). 
1.4.3.2. Protein S-glutathionylation 
 Protein S-glutathionylation has emerged as a strong candidate for the redox-sensitive 
posttranslational modification of proteins. S-glutathionylation is the addition of a glutathione 
molecule to a protein cysteine thiol residue. As opposed to sulfenylation, S-glutathionylation fits 
all the outlined criteria for an effective post translational modification. Proteins have been found 
to contain S-glutathionylation motifs which are cysteine rich amino acid sequences that are 
accessible and surrounded by positively charged lysine residues (96). This latter characteristic is 
vital since it lowers the pKa of a protein cysteine residue, allowing easier deprotonation and the 
formation of a strongly nucleophilic thiolate anion that can attack GSH molecules. A number of 
proteins have been found to be S-glutathionylation targets (Table 1.1) (64). S-glutathionylation 
reactions are catalyzed by GRX, small heat stable thiol oxidoreductases that specialize in the 
conjugation and removal of GSH from a target protein. Notably, GRX mediated S-
glutathionylation reactions are usually 102-105 M-1s-1 with the rate of the reaction increasing with 
a decreasing thiol pKa (96). The GST family has also been implicated in some cellular S-
glutathionylation reactions (97).  
Although S-glutathionylation can be enzymatically mediated, spontaneous S-glutathionylation is 
also able to proceed under the right conditions. During times of oxidative stress, when the 
2GSH/GSSG ratio approaches 1, the increased concentrations of GSSG can lead to non-enzymatic 
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Table 1.1: Known targets of S-glutathionylation 
 
 
 
This table lists mitochondria proteins that are known to be S-glutathionylated as of 2013.  
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protein S-glutathionylation (98). Non-enzymatic S-glutathionylation can also occur when cysteine 
is oxidized to SOH, which can then react with GSH (99). These are likely methods employed to 
protect proteins from irreversible oxidative inactivation when levels of H2O2 in the mitochondria 
are high. A third mechanism of spontaneous S-glutathionylation can also occur when cysteine 
forms a thiol radical that can react with GSH, forming a thiyl radical glutathionyl intermediate, 
which then passes an electron to O2, leaving behind a protein glutathione mixed disulfide (PSSG) 
(99). Some enzymes in the mitochondria are known to show persisted S-glutathionylation during 
normal physiological conditions, such as SDH (100). Conditions that lead to S-glutathionylation 
of proteins in the mitochondria can vary widely, due to some proteins being more susceptible, and 
also due to the highly folded nature of cristae, which can form microenvironments that contain 
highly variable levels of GSSG as compared to the rest of the mitochondria (101).   
 The importance of S-glutathionylation reactions in the mitochondria extends past 
protection from oxidative stress. S-glutathionylation also has roles in energy metabolism, as seen 
by its extensive levels of protein S-glutathionylation found on Krebs cycle enzymes (102). Many 
other mitochondrial processes have also been shown to utilize S-glutathionylation such as 
apoptosis, mitochondrial shape, protein import, and proton leakage.  
1.5. Glutaredoxin 
 GRXs are a family of GSH-dependent thiol oxidoreductases belonging to the thioredoxin 
fold superfamily (70). GRX was first discovered in E. coli, where it was found to catalyze the 
GSH-dependent reduction of ribonucleotide reductase (103). However, it was later found that the 
GSH-mediated modification of proteins was driven by GRX in mouse liver cells (104). This GRX 
isozyme was later identified as mammalian GRX1, a small 10-14 KDa protein located in the 
cytosol and the mitochondrial intermembrane space (103), which functions to keep thiols in the 
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reduced state, mainly by the reduction of PSSG adducts (105). The active site of GRX1 contains 
a Cys-Pro-Tyr-Cys sequence, with cysteine-22 harboring the requisite reductive power to 
deglutathionylate a target protein (105). Deglutathionylation forms a GRX1-SSG intermediate. In 
the second catalytic phase, GRX1-SSG binds GSH which is required to remove the glutathionyl 
moiety via a thiol disulfide exchange reaction that yields reactivated GRX1 and GSSG. GR and 
NADPH are then utilized to reduce GSSG reforming two GSH molecules. Other roles for GRX1 
include dehydroascorbate reduction, cellular differentiation, and regulation of cell signaling and 
apoptosis (106).  
 GRX2 is the second GRX to be discovered in mammals. There are three GRX2 isoforms: 
GRX2a is localized to the mitochondria matrix, while GRX2b and GRX2c are localized to the 
nucleus (106). GRX2a is ubiquitously expressed in the body, while GRX2b and GRX2c are 
expressed exclusively in the testis or cancer cells (107). GRX2 shares about 36% homology with 
mammalian GRX1 (105), one of the most noticeable differences being the Cys-Ser-Tyr-Cys active 
site sequence (106). GRX2 also differs from GRX1 in that it is more resistant to oxidative 
inactivation. GRX1 contains additional protein surface Cys residues that are amenable to 
irreversible oxidation whereas GRX2 does not, allowing it retain activity during periods of 
increased oxidation (70). In addition, unlike GRX1, oxidized GRX2 can be reduced and 
reactivated by TR2 as well as GSH (69).  
 There exist two different mechanisms for the deglutathionylation of proteins by GRX1 and 
GRX2. In the dithiol mechanism, the N-terminal active site cysteine residue attacks a protein-
glutathione disulfide bridge via a simple nucleophilic displacement reaction, releasing the reduced 
protein and a GRX-glutathione mixed disulfide, GRX-SSG (108). GRX-SSG immediately forms 
an intraprotein disulfide bond (GRX-SS), which is then reduced by two molecules of GSH, 
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reforming GRX and releasing GSSG (108). In the monothiol mechanism, the GRX-SSG adduct is 
reduced by GSH, reforming GRX and GSSG (108). These mechanisms can be viewed in Figure 
1.8. To facilitate protein S-glutathionylation, GRX must form an intermediate GRX-SSG•, which 
can react with protein thiols to form PSSG (109).  
 GRX2 can exist in the mitochondria as an active monomer and an inactive dimer (106). 
Closer examination of the structure of GRX2 has revealed that the enzyme contains Fe(III) in a  
tetrahedral sulfur coordination consistent with the presence of an [2Fe-2S]2+ cluster (106). A 
GRX2 dimer forms a [2Fe-2S]2+ cluster stabilized by two active site protein cysteines and two  
cysteines from separate molecules of GSH (110). The role of the Fe-S cluster in GRX2 is to allow 
the enzyme to function as a redox sensor. When mitochondria have low levels of oxidation, GRX2 
exists in the inactive dimer formation. However, during times of oxidative stress, the Fe-S cluster 
is degraded by O2•-, releasing the active GRX2 monomers (106), which can then function to 
catalyze S-glutathionylation reactions to protect enzymes and modulate ROS production.  
GRX2 has been proven to be an important enzyme in maintaining cellular function. 
Overexpression of GRX2 has been found to protect mice from doxorubicin induced cardiac injury 
(111), while silencing GRX2 in HeLa cells increases their sensitivity to the drug (112). Deletion 
of GRX2 was also shown to accelerate the onset and formation of cataracts in mice, due to 
increased formation of PSSG, leading to increases in proteins aggregates (113). GRX2 has also 
been identified to have an important function in embryogenesis, playing a role in both brain (114), 
vascular (115) and cardiac development (116). GRX2 deficiency in mice is associated with the 
development of hypertension, left ventricular hypertrophy, and fibrosis (117). Lastly, GRX2 may 
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be  required to control apoptosis. Overexpression of 
GRX2 in HeLa cells decreases doxorubicin 
 
Figure 1.8: The dithiol and monothiol mechanisms of GRX 
The dithiol mechanism of GRX shows protein deglutathionylation and subsequent oxidation of 
GRX, forming GSH, and next the reduction of GRX with GSH. The monothiol mechanism of 
GRX shows protein deglutathionylation, forming glutathionylated GRX via a thiol exchange. 
Next, the reduction of GRX with GSH via thiol exchange. 
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be required to control apoptosis. Overexpression of GRX2 in HeLa cells decreases doxorubicin 
mediated apoptosis by preventing the release of cytochrome c by cardiolipin, avoiding the 
initiation of the caspase cascade (118). This evidence points to the conclusion that the regulation 
of S-glutathionylation reactions is vital for normal development and function.  
1.6. S-Glutathionylation reactions in ROS formation 
 The modification of enzyme function by S-glutathionylation has been found to be an 
important method of controlling ROS production from certain sites in the mitochondria. The 
addition of GSH causes a variety of outcomes depending on the enzyme and the site of S-
glutathionylation. In some cases, S-glutathionylation can decrease O2•-/H2O2 production, while in 
others it can augment O2•-/H2O2 emission. Some enzymes are only S-glutathionylated when local 
redox buffering networks are more oxidized (e.g. GSSG levels are higher due to increased H2O2 
production), while some are consistently S-glutathionylated during normal physiological 
conditions. So far, S-glutathionylation has been proven to occur on number of vital mitochondrial 
enzymes, altering oxidative phosphorylation and the production of ROS in response to redox 
signals.   
1.6.1. Complex I 
 One of the most studied sites of S-glutathionylation is complex I of the ETC. The effects 
of thiol modification of complex I were first noticed by Balijepalli et al., who found that diethyl 
maleate and iodoacetamide, which binds to protein cysteine thiols, can inhibit its activity (119). 
Notably, this effect could be reversed with the reductant dithiothreitol (DTT). Complex I was also 
found to be inhibited by nitric oxide, due to thiol S-nitrosylation, which could be reversed by the 
addition of GSH (120). This evidence indicated the possibility of a mechanism which controls 
complex I activity by modulating its thiol groups. Complex I was found to contain thiol residues 
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in the NDUSF1 (∼75 KDa) and NDUFV1 (∼51 KDa) subunits which were able to become 
reversibly S-glutathionylated in the presence of GSSG (117, 121, 122). These subunits are located 
on the arm of complex I which protrudes into the matrix (121). Taylor et al. also found that S-
glutathionylation of these complexes correlated with an increase in the concentration of 
mitochondrial ROS (121). In response to decreasing GSH/GSSG ratios, Beer et al. found complex 
I to be one the most persistently S-glutathionylated proteins in the mitochondria (123). Beer et al. 
also discovered that the S-glutathionylation of complex I could be reversed by the addition of 
purified GRX2 (123).  The overall effect of complex I S-glutathionylation on its ROS predicting 
capabilities has shown mixed results. While some studies have shown that S-glutathionylation of 
complex I increases O2•-/H2O2 emission from the enzyme (117, 121), another study has provided 
evidence that it causes decreased ROS production (122). Decreases in ROS production could be 
caused by S-glutathionylation of the NDUSF1 and NDUFV1 subunits in complex I, blocking the 
transfer of hydride ions from NADH to FMN and decreasing the formation of the FMN semi-
radicals and fully reduced flavin molecules that produce ROS (99). S-glutathionylation could also 
block the flow of electrons to the UQ binding site, also lowering the production of ROS. There are 
also possible mechanisms that could explain increases in ROS. S-glutathionylation of ND3 subunit 
in the UQ binding pocket could block electron flow and lead to a buildup of electrons at the FMN 
site, increasing the likelihood of ROS formation (27). During long term complex I S-
glutathionylation, ROS production may also be increased from other sites due the increased levels 
of NADH caused by decreased complex I activity (99).  It has been proposed that the S-
glutathionylation of complex I is ultimately more complex than originally thought, and that 
different S-glutathionylation states of complex I can cause different outcomes in response to 
different stimuli (99). This hypothesis, also known as the “complex I cysteine code”, suggests that 
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S-glutathionylation of certain thiols can cause changes in ROS emission in response to changes in 
the environment.  
1.6.2. Succinate dehydrogenase 
 SDH, also known as complex II of the ETC, is also a significant site of ROS production in 
the mitochondria. SDH has been found to produce ROS from its FAD prosthetic group in the 
SDHA subunit during forward and reverse electron flow through the complex (124). During 
normal physiological conditions SDH is persistently S-glutathionylated on the 70 KDa FAD 
binding subunit, at Cys90 (100). Deglutathionylation of the enzyme causes decreased activity and 
increased production of ROS (100). One hypothesis is that S-glutathionylation of the specified 
residue causes a conformational change in the FAD binding site which increases electron transfer 
away from the flavin site, decreasing electron leakage (100). During ischemia in cardiac tissue, the 
highly reduced environment causes deglutathionylation of SDH, decreasing its activity and 
increasing ROS production (100). Increased levels of oxidation can also inactivate the enzyme, 
suggesting that S-glutathionylation may also act as a protective mechanism (100).  
1.6.3. OGDH and PDH 
 Although in the past complex I was considered the most important source of ROS 
production in the mitochondria, evidence has shown that several other enzymes in mitochondria 
can serve as high capacity sites for O2•-/H2O2 formation. For instance, it was found that Krebs 
cycle enzymes, OGDH (125, 126) and PDH (127), can generation far more O2•-/H2O2 than 
complex I. In skeletal muscle, the OGDH and PDH complexes have been found to produce eight 
and four times as much ROS than complex I, respectively, when NADH is the source of electrons  
(128). Similar observations have been made in cardiac and liver tissue, with OGDH producing 
more ROS than PDH (44). Moreover, it has been found in liver mitochondria that OGDH accounts 
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for ~35% of the ROS formed whereas PDH and complex I generate negligible amounts (62). These 
enzymes have also been shown to produce ROS during reverse electron transfer (e.g NADH is 
oxidized by PDH and OGDH and electrons flow backwards through the enzyme complex) (44). 
This can occur at physiological concentrations of NADH, indicating that reverse electron flow 
through these enzymes is a source of ROS even during normal mitochondrial function (44). Both 
enzymes complexes are likely to be important sites of redox signaling due to the evidence that they 
are major sources of ROS and because they are both essential entry sites for carbon into the Krebs 
cycle.  
 Initial studies have identified OGDH as a redox sensor, meaning that it undergoes changes 
in function in response to levels of ROS in the mitochondria. Nulton-Persson et al. found that 
treatment of mitochondria with H2O2 caused a decrease in oxidative phosphorylation, which was 
linked to a decrease in the activity of OGDH (129). This inactivation was reversed by either DTT 
or GRX1, demonstrating that H2O2 must cause some sort of modification of the sulfhydryl groups 
of OGDH (129). The discovery that OGDH is a source of ROS led to the hypothesis that production 
of ROS from the complex can negatively feedback and inhibit further production (22). Further 
inquiries into the modification of OGDH during oxidative stress showed that the lipoic acid 
residues of the E2 subunit were reversibly S-glutathionylated (130, 131). Since the lipoic acid 
residues of OGDH are susceptible to oxidation by H2O2, S-glutathionylation may be a method to 
keep them protected during times of increased oxidative stress (22). Initially, diminished ROS 
production seen during OGDH S-glutathionylation was considered to be caused by decreased 
NADH production, reducing its oxidation at complex I (22). However, it has been shown that S-
glutathionylation of OGDH can modulate the emission of ROS from the enzyme complex itself 
(44, 61, 132). Depending on where OGDH is S-glutathionylated, production of ROS can be either 
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decreased or increased. S-glutathionylation of the lipoic acid residues of the E2 subunit by GSSG 
leads to decreased O2•-/H2O2 production by blocking the transfer of electrons to the E3 flavin 
group, also coinciding with decreased production of NADH (44, 132). Conversely, when OGDH 
is incubated with increased concentrations of GSH, the E1 subunit becomes S-glutathionylated, 
leading to increased O2•-/H2O2 emission (132). OGDH does generate O2•-/H2O2 from its E1 and 
E3 subunits and thus it is possible that S-glutathionylation of the E1 subunit leads to the 
accumulation of thiamine radicals, which can increase ROS production (132). The accumulated 
evidence indicates that OGDH can serve as a mitochondrial redox sensor that can increase or 
decrease ROS production in response to changes in the GSH/GSSG ratio.   
 Recent work from our laboratory has indicated that like OGDH, ROS production by PDH 
is also controlled by S-glutathionylation (61). Using the S-glutathionylation catalysts, diamide and 
disulfiram, during the forward oxidation of pyruvate, PDH has been found to show decreased O2•-
/H2O2 emission (61). S-glutathionylation of PDH has been confirmed on all three enzyme subunits, 
with the E2 subunit being the most persistently S-glutathionylated (61). This indicates that like 
OGDH, PDH can also be S-glutathionylated on the E2 subunit to decrease ROS emission from the 
complex. PDH has also been shown to facilitate reverse electron flow though the complex, during 
which ROS is produced (44). Incubation of PDH with GSSG caused amplified ROS production 
through reverse electron transport when supplemented with NADH (61). This effect was reversed 
by the addition of GRX2, indicating it was driven by S-glutathionylation (61). S-glutathionylation 
of the E2 subunit of PDH during reverse electron transfer may block the flow of electrons from 
the E3 to the E1 subunit. This may allow for increased passage of electrons from the flavin group 
of the E3 subunit, to O2, increasing the production of ROS (61). During times of increased 
oxidative stress leading to high levels of GSSG and NADH, GRX2 may be an important method 
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to prevent S-glutathionylation of PDH and thereby prevent further increases in ROS production 
from the complex.  
1.6.4. Uncoupling proteins 2 and 3 
 Uncoupling proteins in the mitochondria have also been suggested to influence the 
production of ROS. These proteins can decrease the membrane potential in mitochondria by 
allowing protons to return to the matrix independently of ATP synthase, decreasing the membrane 
potential, which may decrease ROS production. UCP2 and UCP3, which are 73% homologous to 
each other, are integral proteins embedded in the mitochondrial inner membrane and part of the 
solute anion carrier superfamily. ROS production from complex I and III is known to be very 
sensitive to the PMF, therefore it was hypothesized that mitochondrial uncoupling may be a 
possible method of decreasing ROS production by the ETC (78). Over a decade ago, it was found 
that proton leakage through the mitochondrial UCPs can be activated by O2•- (133). This indicated 
that ROS may be able to regulate its own production through a negative feedback loop that 
involved activation of proton leaks through the UCPs. Inhibition or knockout of UCP2 and UCP3 
has been found to increase production ROS, while overexpression of these proteins has the 
opposite effect (80, 82, 83). More recent work has identified that UCP2 and UCP3 can be S-
glutathionylated, which is thought to be required for the regulation of proton return to the matrix 
and the modulation of mitochondrial ROS production (77). UCP2 and UCP3 both contain reactive 
cysteine sites that can be S-glutathionylated, specifically Cys25 and Cys259 in UCP3 (77). S-
glutathionylation of UCP3 causes a decrease in UCP3 mediated proton leak (77). S-
glutathionylation of UCP3 was also discovered to be catalyzed by the enzyme GRX2 (134). In 
GRX2 knock out mice UCP3 was less glutathionylated and proton leak was increased in skeletal 
muscle mitochondria (134). The evidence may suggest a mechanism in which S-glutathionylation 
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of UCPs can alter proton leak, modifying the proton gradient and therefore altering ROS 
production by the ETC. 
1.7. Research objectives 
 The goal of this project was to further characterize the functionality of S-glutathionylation 
reactions in the mitochondria and how this redox sensitive covalent modification alters ROS 
production in liver and cardiac mitochondria metabolizing different substrates and subjected to 
different bioenergetic conditions. Using GRX2 homozygous knock out mice (GRX-/-) and mice 
heterozygous for GRX2 (GRX2+/-), changes in mitochondrial ROS production were measured and 
compared to wildtype (WT) C57BL/6N littermates. Since S-glutathionylation reactions are 
mediated by GRX2 in the mitochondria, the loss of the enzyme would lead to altered S-
glutathionylation states of important ROS production enzymes in the mitochondria. Changes in 
ROS emission from specific sites in the mitochondria was measured using site specific inhibitors.   
1.7.1. Hypothesis 
 My hypothesis is that the loss of GRX2 will lead to deregulated S-glutathionylation in the 
mitochondria, which will cause alteration in ROS emission from key sites, in particular, complexes 
I and II of the ETC and PDH and OGDH of the Krebs cycle.  Specific aims for this project will 
include: 
1. Characterizing the production of ROS in liver and cardiac mitochondria isolated from 
GRX2 deficient mice when supplemented with malate and pyruvate or 2-oxoglutarate.  
2. Characterizing the production of ROS in liver and cardiac mitochondria isolated from 
GRX2 deficient mice, when supplemented with succinate. 
3. Characterizing the change in ROS production in liver and cardiac mitochondria isolated 
from GRX2 deficient mice, when the membrane potential of the mitochondria is altered.  
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2. Materials and Methods 
2.1. Breeding 
Male and female GRX2+/- mice were a gift from Dr. Mary-Ellen Harper (University of 
Ottawa). GRX2+/- mice were generated using the C57BL/6N mouse strain as described in Wu et 
al. 2011 (135). Mice were housed in the animal care unit at room temperature (~23 °C, 12 hour 
(h) dark/12 h light cycle, lights on at 0700 h) and given free access to water and chow (Teklad 
Global 18% Protein Rodent Diet, 2018). Age-matched male and female GRX2+/- mice were paired 
for breeding and the generation of litters containing WT, GRX2+/-, GRX2-/- animals. Male mice 
were removed once it was confirmed female mice were pregnant. After birth, the male pups were 
weaned at 3 weeks of age and ear notched for genotyping. Ear notches were stored at -20 °C. 
Female pups were either kept for future breeding or culled. Male mice were fed a standard grain 
based chow diet (Teklad Global 18% Protein Rodent Diet, 2018) ad libitum and given free access 
to water for up to 10 weeks. Mice were weighed and examined routinely from the age of 4-8 weeks 
to ascertain if GRX2 deficiency caused any alterations in linear growth (change in weight over 
time). It is important to note that two previous studies found that deletion of the GRX2 gene does 
not alter linear growth, food and water consumption, or result in the development of any adverse 
phenotypes that may affect physiological function(s) (117, 134). Animals were cared for in 
accordance with the principles and guidelines of the Canadian Council on Animal Care and the 
Institute of Laboratory Animal Resources (National Research Council). All procedures using mice 
were approved by the Animal Care and Use Committee at Memorial University of Newfoundland.  
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2.2. Genotyping 
2.2.1. DNA extraction 
Mouse genotyping was conducted as described in Mailloux et al. and Wu et al. (117, 135). 
DNA extraction from ear notches was performed using the REDExtract-N-Amp Tissue PCR Kit 
(Sigma-Aldrich) according to the manufacturer’s instructions. Ear notches were placed in separate 
1.5 mL microcentrifuge tubes and treated with 100 L Extraction Solution and 25 L Tissue Prep 
Solution. Samples were then incubated at room temperature for 10 mins followed by a second 
incubation at 95 ºC for 3 mins. This was followed by the addition of 100 L of Neutralization 
Solution to each tube. Samples were then vortexed and used for polymerase chain reaction (PCR). 
Alternatively, samples were stored at -20 ºC for later use.  
2.2.2. Polymerase chain reaction  
Primers for Grx2 were obtained from Integrated DNA Technologies (Table 2.1). Primer 
sequences were provided by Dr. Mary-Ellen Harper (University of Ottawa) and were generated 
based on previously published studies by Mailloux et al. and Wu et al. (134, 135). In a PCR tube 
the following contents were added: 1 L of 0.5 M Grx2 forward primer, 1 M of 0.5 M Grx2 
reverse primer, 1 L of 0.5 M Grx2 neo primer, 4 L of DNA solution, 3 L nuclease-free water 
and 10 L of REDExtract-N-Amp Tissue PCR Kit Reaction Mixture, giving a final volume of 20 
L. DNA sequences were then amplified using an Eppendorf Mastercycler pro PCR System. The 
PCR sequence is shown in Table 2.2.  
2.2.3. Gel electrophoresis 
PCR samples were electrophoresed on a 1.5 % agarose gel which was made by dissolving 
0.75 g of agarose powder (Fisher Scientific) in 0.5X Tris-Borate-EDTA (TBE, 10X solution 
diluted to 0.5X in analytical water) under heat. SYBR Safe DNA Gel Stain (Fisher Scientific)  
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Table 2.1: DNA sequence of primers used for Grx2 genotyping 
Primer Sequence 
Grx2 Forward 5’-GAC CTA GCC TAC CAG ACT TGG CTG AAA TTT ATT C-3’ 
Grx2 Reverse 5’-CAT AGA CAC TCT TCA CTT TCA AGC CCA CCC TC-3’ 
Grx2 Neo 5’-CCT ACA TTT TGA ATG GAA GGA TTG GAG CTA CGG G-3’ 
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Table 2.2: Polymerase chain reaction protocol for Grx2 genotyping 
 Temperature (ºC) Time 
Step 1 94 5 min 
 
Step 2 
30 Cycles 
94 30 sec 
63 1 min 
72 1 min 
Step 3 72 7 min 
Hold 4 ∞ 
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was added to the molten agarose (1/10,000 dilution), which was then poured into the gel molding 
and allowed to solidify. The gel was then set up in a Fisher Biotech Horizontal Electrophoresis 
Systems gel box. Trackit 100 bp DNA Ladder (Fisher Scientific) was used to estimate DNA 
fragment size. Samples were electrophoresed for 40 mins at 90 V. Nucleotide sequences 
corresponding to the amplified Grx2 gene were visualized with the Alpha Innotech ChemiImager 
Ready System. WT mice produced a single nucleotide sequence that was 729 base pairs (bp) in 
length while GRX2-/- mice produced a fragment 510 bp in size. Samples collected from GRX2+/- 
mice contained both nucleotide fragments (510 bp and 729 bp).  
2.3. Mitochondrial isolation 
 All steps were performed on ice or at 4C. Prior to experiments 2 liters of MESH buffer 
(220 mM mannitol, 1 mM EGTA, 70 mM sucrose, and 20 mM HEPES, pH 7.4) was made and 
stored at 4 °C. Note that all substrates and reagents utilized for mitochondrial assays were prepared 
in MESH buffer. Mitochondrial isolation buffer (MESH-B; MESH + 0.5% (w/v) fatty acid-free 
bovine serum albumin (BSA) (Sigma-Aldrich)) was made fresh the day of experiments.  
Mitochondria were isolated from the livers and cardiac tissue of 8-10-week-old mice. Mice were 
deeply anesthetized using isoflurane and euthanized by cervical dislocation. Livers and hearts were 
then harvested and placed in MESH-B buffer, washed of any excess blood, dabbed dry, and 
weighed. Tissues were then cut into small pieces and washed in MESH-B. Tissue pieces were then 
minced with a razor blade and homogenized using the Potter-Elvjham method in 15 mL MESH-B 
(~15 passes with the pestle). Before homogenizing cardiac tissue, 1 unit of subtilisin A (Sigma-
Aldrich), a protease, was added to MESH-B to ensure proteolytic degradation of myofibers and 
the release of intermyofibrillar mitochondria. The amount of protease required was calculated 
using Equation 2.1: 
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Equation 2.1: Calculation of subtilisin A addition 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 1
𝑚𝑔
𝑚𝐿
 𝑠𝑢𝑏𝑡𝑖𝑙𝑖𝑠𝑖𝑛 𝐴 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑢𝑠𝑐𝑙𝑒 (𝑔)
1
𝑚𝑔
𝑚𝐿  𝑥 11.7 
𝑚𝑔
𝑢𝑛𝑖𝑡
 
Liver mitochondria were isolated by first centrifuging the homogenate at 800 x g for 9 
minutes to remove nuclei and any undisrupted tissue. The pellet was discarded and the supernatant 
collected and centrifuged at 10,000 x g for 9 mins. The supernatant was then discarded and the 
pellet was resuspended in 20 mL MESH-B and centrifuged again at 10,000 x g for 9 mins. The 
wash step is vital for the removal of any contaminating organelles. The supernatant was discarded 
and the pellet was resuspended in 500 L MESH buffer devoid of BSA. For cardiac mitochondria, 
the homogenate was centrifuged at 10,000 x g for 9 mins and the supernatant was discarded to 
remove subtilisin A. The pellet was resuspended in 15 mL MESH-B and centrifuged at 800 x g for 
9 mins to remove contaminating organelles and undisrupted myofibers. The supernatant was 
collected and centrifuged at 10,000 x g for 10 mins. The supernatant was discarded and the pellet 
was resuspended in 100 l MESH buffer. Note that BSA was omitted to ensure accurate 
determination of protein equivalents to mitochondria.  
2.3.1. Bradford assay  
The concentration of the mitochondrial samples was determined with the Bradford assay 
(Sigma-Aldrich) using BSA (Sigma-Aldrich) as the standard, with a concentration range of 0 to 
1.875 mg/mL. An aliquot of mitochondrial suspension was diluted by 1000 times in analytical 
water and then vortexed for ~ 5 seconds. Two hundred microliters of Bradford reagent was added 
to a 1.5 mL microcentrifuge tube followed by 50 µL of diluted mitochondrial protein solution. The 
volume was then adjusted to 1 mL with analytical water. After a brief vortex 200 µL aliquots of 
the Bradford mixture was added to individual wells of a clear bottom black 96-well plate (Greiner 
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Bio-One) in duplicate. The final concentration of liver and cardiac mitochondria was calculated 
using the slope of the line and the equation y = mx + b (Figure 2.1). The final concentration of 
liver and cardiac mitochondria was approximately 15-20 mg/mL and 6-10 mg/mL, respectively. 
Samples were then stored on ice for assays. Once assays were completed, remaining samples were 
stored at -80 °C for immunoblot analysis.  
2.4. Amplex Ultra Red assay 
O2•-  is often considered the proximal ROS formed by mitochondria. However, it is now well 
documented that flavin sites (either FAD or FMN) form a mixture of O2•- and H2O2 (44). In 
addition, any O2•- formed is quickly dismutated to H2O2 by endogenous SOD. The production of 
ROS by mitochondria oxidizing different substrates was examined using the Amplex Ultra Red 
(AUR) assay which selectively measures H2O2 levels. However, AUR cannot discriminate 
between H2O2 formed during nutrient oxidation or by the dismutation of O2●-. Thus, for this study 
any measures of ROS emission by mitochondria was denoted as O2●-/H2O2 to account for 1) any 
H2O2 generated directly by sites of production and 2) any H2O2 formed as a consequence of O2●- 
dismutation. Prior to assays, liver and cardiac samples were diluted to 3 mg/mL and 1 mg/mL in 
MESH-B, respectively, and stored on ice. Twenty microliters of liver or cardiac mitochondria 
suspension was then transferred into individual chambers of a black 96-welled plate containing 
MESH-B. Mitochondria were allowed to equilibrate for a few minutes and then AUR assay 
reagents, enzyme inhibitors, and substrates were added. The final volume in each reaction chamber 
was 200 µL and the final concentration of liver and cardiac mitochondria was 0.3 mg/mL and 0.1 
mg/mL protein equivalent to mitochondria, respectively. For all assays, changes in fluorescence 
were tracked at 565/600 nm every 30 seconds for 5 minutes using a SpectraMax M5 plate reader 
at room temperature. 
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Figure 2.1: Examples of Bradford assay standard curve for protein concertation determination 
Increasing concentrations of BSA were mixed with the Bradford reagent at a constant volume and 
absorbance was measured. This allows for samples with unknown protein concentration to be 
determined via absorbance.  
 
 
 51 
Rates of production were calculated using standard curves generated with different concentrations 
of H2O2 (30 % stock solution at 12.8 M, Sigma-Aldrich) ranging from 20-400 nM (Figure 2.2). 
Rates of O2●-/H2O2 production were calculated using Microsoft Excel 2013. 
2.4.1. Measurement of O2•-/H2O2 formation during pyruvate and 2-oxoglutarate 
oxidation 
Mitochondria have been documented to contain up to 11 sources of ROS during nutrient 
metabolism. This includes Krebs cycle enzymes, respiratory complexes I, II, and III, and several 
enzymes that feed electrons directly into the UQ pool. In order to ascertain the effect of GRX2 
deficiency on O2•-/H2O2 from the different sites of production, different substrate and inhibitor 
combinations are used (Figure 2.3). Substrates that feed directly into the Krebs cycle can induce 
ROS production by OGDH, PDH (if pyruvate is present), and the ETC (Figure 2.3). By contrast 
other substrates like succinate or glycerol-3-phosphate donate electrons directly to the UQ pool, 
bypassing the Krebs cycle (Figure 2.3). To determine if GRX2 alters ROS production during Krebs 
cycle metabolism, O2•-/H2O2 emission from liver and cardiac mitochondria was examined using 
either pyruvate (50 µM) or 2-oxoglutarate (50 µM) in combination with malate (50 µM). These 
concentrations were chosen because the physiological concentrations of the substrates are known 
to be in the M range. In addition, our group has shown previously that µM concentration of 
substrate can induce a measurable rate of ROS production (61, 62). Prior to initiating the assay, 
samples were incubated in 10 mM α-keto-β-methyl-n-valeric acid (KMV) (Sigma-Aldrich) or 4 
M myxothiazol (Sigma-Aldrich) for 5 mins at 25 C. KMV is a structural analog for 2-
oxoglutarate and thus selectively inhibits ROS production by OGDH (62). Myxothiazol is a 
selective inhibitor for ROS production by Complex III (62). Briefly, myxothiazol binds to the UQ 
binding pocket near the outer leaflet of the inner membrane (QO site) preventing the formation of 
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Figure 2.2: Examples of AUR assay standard curve for determination of O2•-/H2O2 concentration 
The florescence of increasing known concentrations of H2O2 in MESH buffer was measured with 
the AUR assay in order to produce a standard curve, allowing for the concentration of unknown 
H2O2 to be determined when florescence is measured.  
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Figure 2.3: Sites of action for different inhibitors of the Krebs cycle and ETC 
 
Rotenone blocks the flow of electrons between the UQ site (IQ) of complex to UQ (CoQ). Atpenin 
A5 blocks electrons from travelling between the UQ site of SDH and CoQ. Myxothiazol blocks 
electrons from UQH2 to the UQH2 site of complex III (Q0). KMV is a competitive inhibitor of 
OGDH, blocking electron movement through the complex, decreasing ROS production.  
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semiquinone which drives O2●- formation. The following reagents were then added to all reaction 
chambers: horseradish peroxidase (HRP, 3 U/mL, Sigma-Aldrich), superoxide dismutase (SOD, 
25 U/mL, Sigma-Aldrich), AUR (10 M, Invitrogen) and malate (50 M). SOD was added to 
convert any O2•-  present in the intermembrane space into H2O2. Assays were then initiated by the 
addition of either 50 M pyruvate or 50 M 2-oxoglutarate.  
2.4.2. Measurement of O2•-/H2O2 formation during succinate oxidation  
 Succinate oxidation bypasses the Krebs cycle and Complex I, donating electrons directly 
to the UQ pool in mitochondria (Figure 2.1). Experimental conditions that employ succinate can 
be manipulated to allow for the measurement of ROS production by the ETC only. This can be 
advantageous since it eliminates O2•-/H2O2 production from the Krebs cycle allowing one to zero 
in on which respiratory complex forms the most ROS. To ensure that we were measuring ROS 
formation by only the respiratory complexes, experimental conditions were manipulated to avoid 
priming ROS production by the Krebs cycle. This was achieved by excluding pyruvate which, 
after conversion to acetyl-CoA, can condense with oxaloacetate from succinate metabolism to 
yield citrate. To determine which site produces the most ROS several ETC inhibitors were used 
(Figure 2.3). Liver and cardiac mitochondrial samples were incubated with either 40 M Atpenin 
A5 (Santa Cruz), 4 M myxothiazol or 4 M rotenone (Sigma-Aldrich) for 20 mins at 25 C. 
Atpenin A5 is a selective inhibitor for Complex II where it blocks the UQ binding pocket 
preventing electron flow to Complex I or III (136). Rotenone is a selective inhibitor for Complex 
I which blocks electron flow from Complex II to the ROS forming FMN prosthetic group. After 
the incubation, AUR assay reagents were added to each well as described in section 1.4.1. The 
assay was initiated by the addition of 50 M succinate.  
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2.4.3. Examining the effect of membrane potential on ROS production 
The polarity of the mitochondrial inner membrane and the rate of proton extrusion and 
return can influence mitochondrial ROS production (76). The rate of proton extrusion and return 
and the strength of the PMF can be manipulated by artificially inducing different states of 
respiration or by short circuiting proton return by adding chemical uncouplers. Manipulation of 
the different states of respiration was achieved by exposing mitochondria to four different 
experimental conditions: (1) substrate alone (state 2 respiration), (2) substrate + 1 mM ADP (state 
3 respiration), (3) substrate + 1 mM ADP + 4 g/mL oligomycin (ATP synthase inhibitor, state 4 
respiration, Sigma-Aldrich), and (4) substrate + 1 mM ADP + 4 g/mL oligomycin + 4 M FCCP 
(uncoupled respiration, Sigma-Aldrich). The addition of ADP promotes proton return through 
Complex V of the respiratory chain which lowers the membrane potential. Oligomycin is a specific 
inhibitor for Complex V and thus impedes proton return and ATP production allowing for the 
hyperpolarization of the mitochondrial inner membrane. FCCP is a protonophore that “short 
circuits” the proton gradient by diffusing protons back into the matrix bypassing Complex V. After 
mitochondria were exposed to the four different conditions, assays were initiated by the addition 
of malate (50 M) and pyruvate (50 M) were added to all chambers.  
2.5. Polarographic measurement of oxygen consumption 
The different states of mitochondrial respiration were measured using a Hansatech 
Oxytherm Electrode. Respiratory states were defined as; state 1: mitochondria only, state 2: 
mitochondria + substrate, state 3: mitochondria + substrate + ADP, state 4: mitochondria + 
substrate + ADP + oligomycin, and inhibition of respiration: mitochondria + substrate + ADP + 
oligomycin + antimycin A (Figure 2.4). The electrode was assembled according to the 
manufacturer’s instructions. First, the silver (Ag) anode is inspected for any oxidation (depicted  
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Figure 2.4: The different states of respiration 
State 2 respiration of mitochondria is initiated by the addition of malate and pyruvate. State 3 
respiration occurs once ADP had been added. Oligomycin is added to block ATP synthase and 
induce state 4 respiration which allows the estimation of how much respiration can be attributed 
to proton leakage. Respiration is halted by the addition of antimycin A which binds to complex 
III, blocking the flow of electrons and collapsing the proton gradient. 
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by brown spots). manufacturer’s instructions. First, the silver (Ag) anode is inspected for any 
oxidation (depicted by brown spots).If any oxidation was detected, the Ag anode was polished 
with specialized electrode polish provided by the manufacturer. The electrode was then rinsed well 
and dabbed dry. One drop of KCl (2.3 M, prepared by dissolving 17.5 g of KCl in 100 mL of 
analytical water) was first placed on the platinum (Pt) cathode which was then covered with a piece 
of filter paper and O2-permeant polyvinylidene difluoride (PVDF) membrane. The 
membrane/filter paper composite was then saturated with KCl solution and then held in place by 
a small O-ring which fits snugly around the Pt cathode. The large O-ring was then applied to the 
outer most part of the disk creating a small chamber on top of the Ag anode which was filled with 
KCl. This can be visualized in Figure 2.5. The completed electrode system was then attached to 
the Oxytherm chamber. The chamber was filled with 2 mL of fully oxygenated analytical water 
and heated to 37 ºC with constant stirring. The system was then calibrated by establishing a 100% 
oxygen saturation condition followed by a 0% oxygen condition which was achieved by adding a 
few crystals of sodium dithionite (Sigma-Aldrich) to the chamber. For experiments, the chamber 
was rinsed 5 times with water prior to adding buffer and samples. Mitochondrial samples were 
diluted to 0.5 mg/ml for liver and 0.1-0.2 mg/ml for cardiac in mitochondrial respiration buffer 
(220 mM mannitol, 70 mM sucrose, 1 mM EGTA, 2 mM Hepes, 10 mM KH2PO4, 2 mM MgCl2, 
pH: 7.4). Samples were added to the chamber and equilibrated until oxygen consumption 
stabilized. State 2 respiration was initiated with the addition of 2 mM malate and 10 mM pyruvate. 
State 3 respiration was initiated with the addition of 1 mM ADP. State 4 respiration was initiated 
by adding 4 mg/ml oligomycin. Respiration was ceased with the addition of 4 µM antimycin-A 
(Sigma-Aldrich). Respiratory control ratios (RCR) were calculated as the ratio of state 3 to state 4 
respiration which serves as a proxy measure for the efficiency of mitochondrial ATP production. 
 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Assembly of the Hansatech oxytherm electrode 
(A) The electrode disk showing the positions of the Pt cathode and Ag anode. (B) The order of 
assembly: a drop of KCl buffer overlayed with filter paper and PTFE membrane. The inner O-ring 
was placed on top and pushed down into place. (C) The assembled electrode. The outer O-ring is 
placed in the groove, which is then filled with KCl buffer. 
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Respiration states were measured in WT, GRX2+/- and GRX2-/- mice. WT, GRX2+/- and GRX2-/- 
mitochondrial samples were performed 4 times in duplicate. Respiration rates were then 
normalized to the concentration of protein equivalent to mitochondria.  
2.6. Gel electrophoresis and Immunoblot 
Mitochondria stored at -80 °C were thawed, vortexed vigorously, and then placed on ice. 
Samples were diluted to 1-6 mg/ml in analytical water containing Laemmli buffer (2X stock 
diluted to 1X in water, Bio-Rad) and heated for 10 minutes at 100C. The variable dilution of 
protein samples depended on the amount required to afford proper detection of enzymes of interest 
(e.g. 40 µg of protein was required to detect GRX2 whereas only 10 µg was needed for OGDH). 
Reducing conditions, if used, were induced by adding 2% v/v -mercaptoethanol to each sample 
Electrophoresis buffer was prepared as a 10X solution in analytical water (25 mM Trizma base, 
1920 mM glycine and 1% (v/v) sodium dodecyl sulfate (SDS)) and stored at room temperature. 
On the day of experiments electrophoresis buffer was diluted to 1X in analytical water (100 mL 
10X electrophoresis buffer + 900 mL analytical water). Samples were electrophoresed in 10% SDS 
resolving gel for proteins with a molecular weight > 40 KDa and a 12% SDS resolving gel for 
proteins < 40 KDa. Resolving gels were prepared by first adding 40% acrylamide solution (36.7% 
w/v acrylamide/3.3 % w/v bis-acrylamide, Biorad) to a 50 mL conical tube followed by the 
addition of 4X Trizma/SDS resolving gel solution (1.5 M Trizma base + 0.4% (w/v) SDS in 100 
mL of analytical water, pH 8.8 with 6 N hydrochloric acid (HCl)). The volume was then adjusted 
to 20 mL with analytical water. Gel polymerization was initiated by adding N,N,N',N'-
tetramethylethane-1,2-diamine (TEMED, Biorad) and 1% (w/v) ammonium persulfate solution  
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 (APS, Biorad). The exact recipes for each gel can be found in Table 2.3. The gel solution was then 
quickly poured into the gel cast filling the chamber three quarters of the way from the top of the 
small glass plate. The gel solution was then overlaid with 100% isopropyl alcohol. Once the gel 
had polymerized, the isopropyl alcohol was removed and the top of the gel carefully dabbed dry 
and overlaid with a stacking gel. The stacking gel was prepared by first adding acrylamide solution 
to a 15 mL conical tube (for a 4% (v/v) acrylamide concentration only 1 mL was required). This 
was followed by the addition of 2.5 mL of 4X Trizma/SDS stacking gel solution (0.5 M Trizma 
Base + 0.4% (w/v) SDS in 100 mL, pH 6.8). The volume was adjusted to 10 mL with analytical 
water and then gel polymerization was initiated by the addition of TEMED and APS. The gel 
solution was then quickly placed on top of the resolving gel and then a 1 mm wide 15 well comb 
was inserted into the stacking gel. Once polymerized the comb was removed and the wells were 
dabbed dry.  
Samples were loaded into the gel and the Mini-protean Tetra System (Bio-Rad) apparatus 
was filled with electrophoresis buffer (2.5 mM Trizma base, 192 mM glycine and 0.1% v/v SDS). 
Samples were electrophoresed at 80 V through the stacking gel. Once the running front penetrated 
the resolving gel the voltage was increased to 240 V. Fifteen microliters of PageRuler Plus 
Prestained protein ladder (Fisher Scientific) was also loaded into each gel to track protein 
migration, gel transfer efficiency, and confirm the molecular weight of proteins of interest detected 
by immunoblot. Gels were stopped once the running front reached the bottom of the gel. Gels were 
then removed from the electrophoresis apparatus and equilibrated for at least 15 minutes in 1X 
transfer buffer. A 10X transfer buffer solution was prepared in advance and stored at room 
temperature (500 mM Trizma, 380 mM glycine, 10% w/v SDS). One times transfer buffer solution 
was prepared the day of experiments by diluting 100 mL of buffer in 800 mL of analytical water  
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Table 2.3: Immunoblot gel recipes 
 4X 
Tris/SDS 
8.8 Buffer 
(mL) 
4X Tris/SDS 
6.8 Buffer 
(mL) 
40% 
Acrylamide/Bis 
Solution (mL) 
Analytical 
water 
(mL) 
TEMED 
(L) 
APS (L) 
10% 
Resolving 
Gel 
5 0 5 10 150 75 
12% 
Resolving 
Gel 
5 0 6 9 150 75 
4% 
Stacking 
Gel 
0 2.5 1 6.5 75 50 
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and 100 mL methanol. Extra thick blotting paper (Bio-Rad), electroblotting sponges (Bio-Rad), 
and nitrocellulose membranes (Bio-Rad) were also equilibrated for at least 15 mins in transfer 
buffer. Proteins were electroblotted onto a nitrocellulose membranes (Bio-Rad) for one hour at 
120 V at room temperature in transfer buffer with the Mini Trans-Blot Electrophoretic Transfer 
Cell (Bio-Rad). Successful transfer was confirmed with Ponceau-S (Sigma-Aldrich) staining. 
Membranes were then blocked at room temperature for at least one hour under constant agitation 
in a blocking solution consisting of Tris-buffered saline (TBS; 1mM Trizma base and 68 mM 
NaCl) containing 0.1% (v/v) Tween-20 (Bio-Rad) (TBS-T) and 5% (w/v) non-fat skim milk (Lab 
Scientific). After three, 5 min room temperature washes in TBS-T, membranes were probed with 
primary antibodies diluted in TBS-T + 5% (w/v) BSA + 2% (w/v) NaN3 (Sigma-Aldrich). Primary 
antibodies used included anti-OGDH (Abcam, catalogue #ab137773), anti-PDH cocktail 
(Mitoscience, catalogue #ab110416), anti-GRX1 (Abcam, catalogue #ab45953), anti-GRX2 
(Abcam, catalogue #ab191292), anti-GSH (Abcam, catalogue #ab19534), anti-SOD (Santa-Cruz, 
catalogue #sc-30080) and anti-SDHA (Santa-cruz, catalogue #sc-377302). Further details on the 
dilution factor for each antibody and the amount of protein utilized for detection can be found in 
Table 2.4. The membrane was incubated in the primary antibody solution overnight at 4C while 
shaking continuously. The membranes were rinsed 3 times with TBS-T for 5 mins at room 
temperature. Membranes were then incubated in secondary goat antibody conjugated to HRP 
diluted in blocking solution, either anti-mouse or anti-rabbit, depending on the primary antibody, 
for 70 mins while shaking at room temperature. Immunoreactive bands were visualized using 
WestPico Super Signal Chemiluminescent substrate and the ImageQuant LAS 4000 system. Band 
intensities were quantified using ImageJ software. Blots were performed in triplicate.  
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Table 2.4: Immunoblot specifications 
Immunoblot 
(Primary Ab) 
Tissue Amount 
of 
protein 
loaded 
per well 
(g) 
Acrylamide 
gel 
percentage 
(%) 
Primary 
Ab 
dilution 
(L) 
Secondary 
Ab-HRP 
conjugate 
dilution 
(L) 
Loading 
control and 
dilution (L) 
Secondary 
Ab-HRP 
conjugate 
dilution 
(L) 
OGDH 
(polyclonal) 
Liver 20 10 1/3000 
 
Goat anti-
rabbit 
1/3000 
 
 
SOD 
1/2000 
(polyclonal) 
 
 
 
Goat anti-
rabbit  
1/3000 
Cardiac 10 10 
PDH 
(monoclonal) 
Liver 20 10 1/3000 Goat anti-
mouse 
1/3000 Cardiac 10 10 
GRX1  
(polyclonal) 
Liver 30 12 1/2000 
 
Goat anti-
rabbit 
1/3000 
 
 
SDHA 
1/3000 
(monoclonal) 
 
 
 
Goat anti-
mouse  
1/3000 
Cardiac 60 12 
GRX2 
(polyclonal) 
Liver 40 12 1/500 Goat anti-
rabbit 
1/3000 
GSH 
(monoclonal) 
Liver 20 10 1/500 Goat anti-
mouse 
1/3000 
None N/A 
Cardiac 
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2.7. Data analysis 
All data analysis was performed with Graphpad Prism 6 software. Unpaired T-tests were 
used for comparison between two groups, one-way analysis of variance (ANOVA) with Fischer’s 
least significant difference (LSD) test was used for comparison between multiple groups. A one-
way ANOVA test was used to test for significant difference in ROS production between the 
genotypes. The significance within the genotypes when using inhibitors was not tested, as these 
inhibitors have already been proven to significantly inhibit ROS production. LSD is an appropriate 
post-hoc test for this data as the experiments are well controlled and do not contain many variables. 
Values are presented as mean + standard error of mean (SEM). Statistical significance was 
calculated and indicated (****P < 0.0001, ***P < 0.001, **P < 0.01 and *P < 0.05). 
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3. Results 
3.1. Profile of GRX2 deficient mice  
3.1.1. Mouse genotyping and confirmation of GRX2 deficiency 
 Successful deletion of GRX2 was achieved by the elimination of the second exon of the 
gene encoding the enzyme (135). This resulted in the production of a shortened Grx2 gene that is 
510 bp in length. This is in contrast to the WT Grx2 gene product, which is 729 bp long. Mice 
heterozygous or homozygous for the truncated Grx2 gene were identified by PCR amplification 
and agarose gel electrophoresis. As shown in Figure 3.1, amplification of the Grx2 gene by PCR 
allowed for easy identification of WT, GRX2+/-, and GRX2-/- mice in different litters. WT mice 
contain a Grx2 gene sequence that is 729 bp while GRX2-/-mice have a truncated form that is 510 
bp long (Figure 3.1). Mice heterozygous for GRX2 contain both bands at 510 and 729 bp, 
respectively. GRX2 enzyme deficiency was confirmed by immunoblotting for the thiol 
oxidoreductase in mitochondria prepared from liver (Fig. 3.2). GRX2 protein expression was 
completely abolished in the knockout mice, while GRX2+/- mice did not show a significant 
difference in GRX2 expression from that of WT mice (Fig. 3.2). 
3.1.2. Effect of GRX2 deficiency on total body and organ weight 
 Mice deficient in GRX2 were monitored for changes in overall body weight and liver and 
cardiac weight. It was shown in a previous study that GRX2-/- mice displayed a very small decrease 
in total body weight when compared to WT littermates fed a standard chow diet ad libitum (134). 
In this study, GRX2-/- and GRX2+/- mice did not show any significant differences in body weight 
from 4-8 weeks of age (Fig. 3.3).  Previous studies have also shown an increase in cardiac weight 
in GRX2-/- and GRX2+/- mice, which is associated with increased cardiomyocyte size, left 
ventricular hypertrophy, and fibrosis (117). However, excised hearts from 8-10-week-old 
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Figure 3.1: Gel electrophoresis of PCR Grx2 gene amplification 
The 729 bp band represents full length Grx2 product (WT) and the 510 bp band corresponds to 
Grx2 devoid of exon 2 (GRX2-/-). Mice harboring both bands are GRX2+/-.  
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Figure 3.2: Confirmation of GRX2 deficiency 
Protein abundance of GRX2 was measured in liver mitochondria samples from WT, GRX2+/-, and 
GRX2-/- mice. (A) Immunoblot of GRX2 abundance in each genotype. (B) Densitometry analysis 
of GRX2 immunoblot using ImageJ software. GRX2 was found to be significantly decreased in 
GRX2-/- mice, as compared to WT mice. Succinate dehydrogenase subunit A (SDHA) was used 
as the loading control. N=3, mean + SEM. This blot was completed by my supervisor, Dr. Ryan 
Mailloux.  
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Figure 3.3: Overall body weight of GRX2 deficient mice 
WT, GRX2+/-, and GRX2-/- mice were weighed weekly from 4 to 8 weeks of age. No significant 
difference in weight was noticed between genotypes at any age. N=12-21, mean  SEM, one-way 
ANOVA with a Fischer’s LSD post-hoc test.  
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GRX2-/- and GRX2+/- mice did not show any significant changes in heart weight (Fig. 3.4A). Livers 
from GRX2 deficient mice also did not show any differences in weight as compared to WT mice, 
an observation that is consistent with previous findings (Fig. 3.4B) (134).   
3.1.3. GRX2 deficiency does not induce a compensatory increase in GRX1 expression  
 GRX1 is a GRX2 isoform that localizes to the cytosol and mitochondrial intermembrane 
space. The abundance of the GRX1 thiol oxidoreductase in mitochondria isolated from liver and 
cardiac tissue was examined by immunoblot to determine if GRX2 deficiency caused any 
compensatory increases in GRX1 abundance. GRX2-/- and GRX2+/- mice did not show any 
significant increases in the protein abundance of GRX1 when compared to WT mice (Fig 3.5). The 
densities of the bands in Figure 3.5 were still within the quantitative range of the antibody. GRX2 
plays a vital role in conjugating and removing GSH from protein cysteine thiols. It was reported 
in two previous studies that complete ablation of the Grx2 gene results in a significant increase in 
the overall number of S-glutathionylated proteins in mitochondria (134, 135). As shown in Figure 
3.6, GRX2+/- mice also displayed a significant increase the total number of mitochondrial proteins 
modified by GSH. Electrophoresis was carried out under nonreducing conditions to preserve the 
S-glutathionylated proteome. To confirm antibody specificity, samples were also treated with β-
mercaptoethanol, a strong reducing agent known to reverse protein S-glutathionylation. Figure 3.6 
demonstrates that conducting the electrophoresis under reducing conditions almost completely 
abolishes the presence of immunoreactive bands corresponding to S-glutathionylated proteins.   
3.2. Examination of the O2●-/H2O2 release potential of GRX2 deficient mitochondria 
3.2.1. O2●-/H2O2 release by liver mitochondria oxidizing Krebs cycle-linked substrates 
 Protein S-glutathionylation is known to alter O2●-/H2O2 production from different sites in 
mitochondria including complex I, OGDH, and PDH (61, 121). However, whether or not GRX2  
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Figure 3.4: Cardiac and liver weight in GRX2 deficient mice 
(A) Hearts and (B) livers were excised from mice of each genotype at 8-10 weeks of age and 
weighed. Cardiac weight was normalized to femur length. No significant difference in weight was 
noticed in either organ between the three genotypes. N=12-21, mean + SEM, one-way ANOVA 
with Fischer’s a LSD post-hoc test.  
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Figure 3.5: There is no compensatory increase in GRX1 protein expression in GRX2 deficient 
mice 
The relative protein abundance of GRX1 was measured by immunoblot in mitochondrial samples 
from (A) liver and (B) cardiac tissue in each genotype. Densitometry analysis (C & D) was 
performed on the resulting bands with ImageJ software. No significant changes in protein 
abundance was noted compared to WT mice. N=3, mean + SEM, one way ANOVA with a 
Fischer’s LSD post-hoc test. 
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Figure 3.6: GRX2 deficiency increases the overall number and intensity of immunoreactive 
bands corresponding to PSSG adducts 
(A) The abundance of PSSG adducts was measured by immunoblot in WT and GRX2+/- 
mitochondria isolated from liver and cardiac tissue. Non-reducing conditions were initiated with 
-mercaptoethanol. (B) Densitometry analysis of the resulting liver bands was performed with 
ImageJ software. (C) Densitometry analysis of the resulting cardiac bands was performed with 
ImageJ software. N=3, mean + SEM, unpaired t-test.   
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controls O2●-/H2O2 release from these sites has not been studied. Thus, we decided to profile the 
O2●-/H2O2 forming capacity of liver and cardiac mitochondria oxidizing different substrates. The 
rate of O2●-/H2O2 production was first examined in liver mitochondria treated with or without 
KMV or myxothiazol, two potent inhibitors for ROS production by OGDH and complex III, 
respectively. Mitochondria were supplemented with 50 M malate, to replenish Krebs cycle 
intermediates, and then treated with either 50 M pyruvate (Fig. 3.7A) or 50 M 2-oxoglutarate 
(Fig. 3.7B) to stimulate Krebs cycle metabolism and ROS production. Liver mitochondria prepared 
from GRX2+/- and GRX2-/- mice displayed no significant change in O2●-/H2O2 release when 
compared to WT mitochondria regardless of which substrate was being oxidized (Fig 3.7A and 
Fig 3.7B). In addition, no differences were observed with mitochondria treated with KMV or 
myxothiazol. Notably, KMV, a structural analog of 2-oxoglutarate and site-specific inhibitor for 
OGDH, induced a ~85% decrease in O2●-/H2O2 emission from liver mitochondria isolated from 
WT, GRX2+/-, and GRX2-/- mice metabolizing either pyruvate or 2-oxoglutarate (Fig 3.7A and Fig 
3.7B). This indicates that OGDH, not PDH, is a high capacity site for O2●-/H2O2 production in 
liver mitochondria, even when pyruvate and malate serve as substrates. Myxothiazol, on the other 
hand, induced a ~30% decrease in O2●-/H2O2 production by mitochondria metabolizing pyruvate 
or 2-oxoglutarate (Fig 3.7A and Fig 3.7B). It is important to point out that the concentrations of 
inhibitors used represent the amount required to achieve maximal inhibition of ROS production 
by either site of O2●-/H2O2 formation (62). Myxothiazol has been shown to cause inhibition of 
complex I, but the effect is small (137) and likely does not affect these results. Overall, these results 
confirm findings from a previous study that showed OGDH and Complex III were the highest 
capacity sites for O2●-/H2O2 release in liver mitochondria (62).  
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Figure 3.7: O2●-/H2O2 production rates in liver mitochondria oxidizing pyruvate or 2-
oxoglutarate 
Liver mitochondria (0.3 mg/ml) were supplemented with 50 µM malate and either 50 µM (A) 
pyruvate or (B) 2-oxoglutarate. Mitochondria were treated with 10 mM KMV or 4 µM 
myxothiazol to examine the source of O2●-/H2O2. The rate of O2●-/H2O2 production was measured 
using AUR at 565/600 nm. N=4-6, mean + SEM, one-way ANOVA with a Fisher’s LSD post-hoc 
test. 
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 Enzyme concentration plays a vital role in dictating in how much O2●-/H2O2 will be formed 
by a particular site of production (e.g. as the [electron donating site] increases, so will the potential 
for ROS production). Thus, the overall abundance of PDH and OGDH in WT, GRX2+/-, and 
GRX2-/- liver mitochondria was assayed by immunoblot. OGDH displayed a significant increase 
in abundance in GRX2-/- mitochondria when compared to WT (Fig. 3.8). Large differences are 
seen in the abundance of PDH subunits in the WT mice due to E1, E2, and E3 being present in a 
40:40:20 ratio (138). In addition, all three subunits for PDH were significantly higher in liver 
mitochondria isolated from GRX2-/- mice (Fig. 3.8). These findings prompted us to normalize the 
O2●-/H2O2 production rates in Figure 3.6 to the relative abundance of OGDH and PDH. 
Normalization of the results to the relative abundance of an enzyme complex is a commonly 
accepted method (139). In Figure 3.9A, the rate of O2●-/H2O2 production from pyruvate 
supplemented mitochondria was normalized to the abundance of the E2 subunit of PDH. 
Normalization of the rate of O2●-/H2O2 production to PDH levels revealed that liver mitochondria 
from GRX2-/- mice displayed a significant decrease in O2●-/H2O2 emission when compared to WT 
(Fig. 3.9A). Similar observations were made with liver mitochondria metabolizing 2-oxoglutarate 
(Fig. 3.9B). Indeed, a decrease in O2●-/H2O2 production was observed in GRX2 deficient 
mitochondria following the normalization of O2●-/H2O2 production rates to OGDH abundance 
(Fig. 3.9B). These observations confirm previously published studies showing that the protein S-
glutathionylation of OGDH and PDH decreases O2●-/H2O2 emission from either enzyme complex 
(44, 61). Moreover, these findings show that GRX2 is required to modulate the reversible S-
glutathionylation of both proteins, an observation our group has made in two separate publications 
(44, 61). 
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Figure 3.8: Protein abundance of OGDH and PDH in liver mitochondria of GRX2 deficient mice 
(A) Immunoblot with liver mitochondrial samples using anti-OGDH (B) Immunoblot with liver 
mitochondrial samples using anti-PDH cocktail. Note that the loading control was performed on a 
separate blot with the same concentrations and conditions. (C) Densitometry analysis was 
performed on OGDH blot with ImageJ analysis. (D) Densitometry analysis was performed on PDH 
blot with ImageJ analysis MnSOD was used as a loading control. N=3, mean + SEM, one-way 
ANOVA with a Fischer’s LSD post-hoc test.   
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Figure 3.9: Production of O2●-/H2O2 in liver mitochondria supplemented with pyruvate or 2-
oxoglutarate normalized to enzyme content.  
Liver mitochondria (0.3 mg/ml) were supplemented with 50 µM malate and with either 50 µM (A) 
pyruvate or (B) 2-oxoglutarate. Mitochondria were treated with either 10 mM KMV or 4 µM 
myxothiazol to examine the source of O2●-/H2O2. The rate of O2●-/H2O2 production was measured 
using AUR at 565/600 nm. N=4-6, mean + SEM, one-way ANOVA with a Fisher’s LSD post-hoc 
test. Results were normalized to either the expression of the PDH E2 subunit or the OGDH E1 
subunit as determined from immunoblotting. 
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3.2.2. O2●-/H2O2 release by cardiac mitochondria oxidizing Krebs cycle-linked substrates 
 Mice deficient for GRX2 develop left ventricular hypertrophy and fibrosis, hypertension, 
and metabolic inflexibility (117), indicating that deregulation of S-glutathionylation reactions in 
mitochondria can potentially cause cardiovascular disease. On a molecular level, the loss of GRX2 
in cardiac mitochondria induces an increase in overall mitochondrial ROS production, an effect 
that is associated with a ~50% decrease in oxidative phosphorylation (117). It is important to point 
out though that the O2●-/H2O2 release capacity of GRX2 deficient cardiac mitochondria was never 
profiled. Thus, we decided to examine the impact of GRX2 deficiency on O2●-/H2O2 production in 
WT and GRX2 deficient cardiac mitochondria oxidizing either 50 M pyruvate or 50 M 2-
oxoglutarate with 50 µM malate. KMV and myxothiazol were used to pinpoint the location of O2●-
/H2O2 production. No significant differences in the rate of O2●-/H2O2 production between the 
GRX2 deficient and WT mice were noticed when the mitochondria were oxidizing either substrate 
(Fig. 3.10A and Fig. 3.10B). The inhibitors, KMV and mxyothiazol, had the opposite effect on 
O2●-/H2O2 release rates in cardiac mitochondria when compared to results collected with liver 
mitochondria (Fig. 3.7). In mitochondria metabolizing pyruvate, KMV and myxothiazol both 
elevated O2●-/H2O2 emission from cardiac mitochondria isolated from WT and GRX2 deficient 
mice (Fig. 3.10A). Collectively, these findings indicate that high capacity sites for O2●-/H2O2 
production differ between liver and cardiac mitochondria. Indeed, in this and a previous study, it 
was found that OGDH and complex III represent the major sources for O2●-/H2O2 production in 
liver mitochondria (62). By contrast, complex I and III have been documented to serve as chief 
sources of O2●-/H2O2 in cardiac mitochondria (43, 63).  
 Due to the significant changes in PDH and OGDH abundance in GRX2 deficient liver 
mitochondria, we also decided to look for any changes in the protein abundance levels of both  
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Figure 3.10: Production of O2●-/H2O2 in cardiac mitochondria supplemented with pyruvate or 2-
oxoglutarate 
Cardiac mitochondria (0.1 mg/ml) were supplemented with 50 µM malate and either 50 µM (A) 
pyruvate or (B) 50 M 2-oxoglutarate. Mitochondria were inhibited with either 10 mM KMV or 
4 µM myxothiazol to examine the source of O2●-/H2O2. The rate of O2●-/H2O2 production was 
measured using AUR at 565/600 nm. N=4-6, mean + SEM, one-way ANOVA with a Fisher’s LSD 
post-hoc test. 
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complexes in cardiac mitochondria via immunoblotting. There was no significant difference in 
either complex between WT and GRX2 deficient mice (Fig. 3.11). In the liver, increased S-
glutathionylation and inactivation of PDH and OGDH caused by GRX2 loss may induce increases 
in their abundance. This effect may not be present in cardiac mitochondria, which may experience 
less S-glutathionylation of Krebs cycle enzymes in GRX2 deficiency. 
3.2.3. O2●-/H2O2 release by liver and cardiac mitochondria supplemented with succinate 
 Complexes I, II, and III are significant sources of O2●-/H2O2 and complexes I and II are 
also known targets for S-glutathionylation, while complex III may also be a target (86, 121, 140). 
Thus, we decided to examine the effect of GRX2 deficiency on succinate-driven O2●-/H2O2 
production. Using succinate supplemented mitochondria also has the added advantage of 
examining O2●-/H2O2 production exclusively by the respiratory complexes since succinate cannot 
be metabolized any further by the Krebs cycle following its oxidation to fumarate. Liver 
mitochondria from GRX2+/- mice displayed a significant increase in O2●-/H2O2 release during 
succinate oxidation (Fig. 3.12A). However, this trend did not hold for mitochondria isolated from 
GRX2-/- mice (Fig. 3.12A). In addition, rotenone, atpenin A5, and myxothiazol, inhibitors for 
complexes I, II, and III, respectively, had little to no effect on succinate-driven O2●-/H2O2 
production. Indeed, inhibition of complex I with rotenone, as well as complex II with atpenin A5, 
had little effect on the rate of O2●-/H2O2 production in liver mitochondria (Fig. 3.12A). Inhibition 
of complex III with myxothiazol did induce a minor decrease in O2●-/H2O2 production which 
confirms that complex III is a significant source of ROS in liver mitochondria (62). The low levels 
of O2●-/H2O2 produced from succinate supplementation, as well as the minor effect of these ETC 
inhibitors, indicates that the ETC complexes, particularly complexes I and II, are not a major 
source of O2●-/H2O2 in liver mitochondria.   
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Figure 3.11: Immunoblot of OGDH and PDH cardiac abundance between genotypes 
A) Immunoblot with cardiac mitochondrial samples using anti-OGDH B) Immunoblot with 
cardiac mitochondrial samples using anti-PDH cocktail. C) Densitometry analysis was performed 
on OGDH blot with ImageJ analysis. D. Densitometry analysis was performed on PDH blot with 
ImageJ analysis. MnSOD was used as a loading control. N=3, mean + SEM, one-way ANOVA 
with a Fischer’s LSD post-hoc test.   
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Figure 3.12: Sources of O2●-/H2O2 production in succinate supplemented mitochondria 
(A) Liver mitochondria (0.03 mg/ml) or (B) cardiac mitochondria (0.01 mg/ml) were 
supplemented with 50 µM succinate. Mitochondria were inhibited with either 40 µM atpenin A5, 
4 µM myxothiazol or 4 µM rotenone to examine the source of O2●-/H2O2. The rate of O2●-/H2O2 
production was measured using AUR at 565/600 nm. N=5, mean + SEM, one-way ANOVA with 
a Fisher’s LSD post-hoc test 
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The results above indicate that succinate is a poor substrate for O2●-/H2O2 production in liver 
mitochondria. By contrast, succinate served as an excellent substrate for O2●-/H2O2 release in 
cardiac mitochondria (Fig. 3.12B). O2●-/H2O2 production displayed a significant increase (almost 
2-fold higher) in cardiac mitochondria isolated from GRX2+/- and GRX2-/- mice (Fig. 3.12B). In 
addition, succinate-induced O2●-/H2O2 production by cardiac mitochondria was inhibited by 
rotenone, atpenin A5, and myxothiazol. Rotenone is a competitive inhibitor for complex I that 
binds the UQ binding pocket, preventing reverse electron flow from complex II. Since the use of 
rotenone induced a significant decrease in O2●-/H2O2 production during succinate oxidation, we 
can deduce that reverse electron flow from succinate to complex I is a major source of O2●-/H2O2 
in cardiac tissue. Similar reasoning can apply to complex III - myxothiazol blocks the UQH2 
binding site of complex III preventing the accumulation of semiquinone radical, a vital source of 
ROS in mitochondria. It is possible that some decrease in ROS production may be due to 
membrane potential collapse by mxyothiazol, but it has been established that myxothiazol does 
decrease ROS production by decreasing the formation of semiquinone in complex III (62). Indeed, 
myxothiazol supplementation almost completely abolished mitochondrial O2●-/H2O2 production 
(Fig. 3.12B).  Atpenin A5, on the other hand, selectively binds the UQ binding site upstream from 
the FAD center in complex II. Similar to rotenone and myxothiazol, atpenin A5 treatment almost 
completely abolished mitochondrial O2●-/H2O2 release (Fig. 3.12B). The FAD center serves as the 
electron donating site for O2●-/H2O2 production in complex II. Therefore, if complex II was a 
significant source of ROS, blocking the UQ binding site with atpenin A5 would augment O2●-
/H2O2 production during succinate oxidation. Since this is not the case, it can be concluded that 
complexes I and III are high capacity sites for ROS production in cardiac mitochondria. 
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3.2.4. Tissue specific effect of substrates in O2●-/H2O2 production 
 In C57Bl/6N WT mice, it was observed that there were tissue specific effects in terms of 
the capacity of different substrates to stimulate O2●-/H2O2 release from mitochondria. For example, 
it was observed that 2-oxoglutarate and pyruvate served as better substrates for O2●-/H2O2 
production in liver mitochondria (Fig. 3.7) in comparison to cardiac mitochondria (Fig. 3.10). By 
contrast, opposite trends were observed when succinate served as the oxidizable substrate (Fig. 
3.12). Overall, this suggests that liver and cardiac mitochondria utilize different enzymes as high 
capacity sites for O2●-/H2O2 production. To examine this effect further, the O2●-/H2O2 production 
rates for liver and cardiac mitochondria oxidizing pyruvate, 2-oxoglutarate, or succinate was 
compared (Fig. 3.13). It was observed that pyruvate and 2-oxoglutarate were ~2-3-fold more 
effective than succinate at generating O2●-/H2O2 in liver mitochondria. By contrast, succinate was 
~4-fold more effective at stimulating O2●-/H2O2 release in cardiac mitochondria in comparison to 
pyruvate or 2-oxoglutarate (Fig. 3.13). The capacity of succinate to stimulate O2●-/H2O2 production 
in cardiac and liver mitochondria was also compared. As shown in Figure 3.13B, succinate was 
~4x more for effective and inducing O2●-/H2O2 emission from cardiac mitochondria. Opposite 
findings were made with 2-oxoglutarate and pyruvate. Indeed, pyruvate and 2-oxoglutarate were 
~2-fold more effective at stimulating O2●-/H2O2 formation in liver mitochondria (Fig, 3.13C & 
3.13D). Collectively, these findings demonstrate that liver and cardiac mitochondria utilize 
different enzyme combinations as high capacity sites for O2●-/H2O2 production. Moreover, these 
findings confirm a recent publication by Slade et al. which demonstrated that OGDH and complex 
III are the main sources of O2●-/H2O2 in the liver whereas complex I and III are the chief sites in 
cardiac tissue (43, 63). 
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Figure 3.13: Tissue specific effects of different substrates on wildtype mice 
(A) Wildtype C57Bl/6N mitochondria supplemented 50 µM of various substrates. (B) Wildtype 
C57Bl/6N mitochondria supplemented with 50 µM succinate. Wildtype C57Bl/6N mitochondria 
supplemented with 50 µM malate and either 50 M (C) pyruvate or (D) 2-oxoglutarate. AUR 
florescence was measured at 565/600 nm. Stars represent significant differences between tissues 
while hashes represent significant differences within tissues, between genotypes. N=4-6, mean + 
SEM, (A) two-way ANOVA with a Fisher’s LSD post-hoc test, (B, C, & D) unpaired t-test. This 
figure shows replotted data from the previous data to highlight key differences.     
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3.2.5. GRX2 loss on proton gradient driven O2●-/H2O2 production 
 The polarity of the mitochondrial inner membrane has been shown to play an integral role 
in influencing mitochondrial ROS production in various tissue types. In addition, protein S-
glutathionylation and GRX2 have been shown to modulate proton return to the matrix and the 
strength of the mitochondrial membrane potential (134, 141). Therefore, we decided to examine 
the impact of GRX2 deficiency on O2●-/H2O2 production in mitochondria displaying differences 
in the rate of proton return to the matrix. In order to vary proton return, mitochondria were 
subjected to different respiratory states (states 2-4) which correspond to the stepwise addition of 
substrate, ADP, and oligomycin to a reaction chamber. Mitochondria were also supplemented with 
FCCP, a protonophore, to test the impact of proton gradient uncoupling on ROS production. The 
addition of pyruvate and malate induces state 2 respiration which corresponds to an increase in 
membrane potential. The addition of ADP stimulates state 3 respiration which augments proton 
return to the matrix through complex V lowering the membrane potential. Introducing oligomycin 
to the system causes the mitochondria to enter state 4 respiration. Oligomycin binds to the F0 
subunit of ATP synthase, blocking the return of protons to the matrix, which leads to 
hyperpolarization of the inner membrane. The addition of FCCP increases proton return to the 
matrix, dissipating the membrane potential. According to the prevailing theories, increasing the 
proton gradient should lead to an increase in the rate of mitochondrial ROS production, due to a 
slowing of electron transfer through the respiratory chain and an over-reduction of electron 
donating sites in the complexes. Likewise, decreasing the potential should lead to a decreased rate 
of mitochondrial ROS production. To our surprise induction of proton return with ADP or FCCP 
augmented O2●-/H2O2 production in liver and cardiac mitochondria (Fig. 3.14). The addition of 
oligomycin did lead to an increase in O2●-/H2O2 production in both tissues, which may be  
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Figure 3.14: Production of O2●-/H2O2 during state 3 respiratory conditions between genotypes 
(A) Liver mitochondria (0.03 mg/ml) or (B) cardiac mitochondria (0.01 mg/ml) were incubated 
with 50 µM malate and pyruvate, and then either 1 mM ADP, 1 mM ADP + 4 µg/ml oligomycin 
or 1 mM ADP + 4 µg/ml oligomycin + 4 µM FCCP to examine O2●-/H2O2 production. The rate of 
O2●-/H2O2 production was measured using AUR at 565/600 nm. N=3-5, mean + SEM, one-way 
ANOVA with a Fischer’s LSD post-hoc test.  
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associated with the hyperpolarization of the mitochondrial inner membrane (Fig. 3.14). Our results 
indicate that there may not necessarily be a relationship between the mitochondrial membrane 
potential and the rate of O2●-/H2O2 production.  
 In the liver mitochondria (Fig. 3.14A), there was a significant decrease in the rate of O2●-
/H2O2 production for GRX2+/- when the proton gradient was dissipated with FCCP. A more intense 
difference between genotypes was noticed in the cardiac mitochondria, where GRX2+/- mice 
showed decreased rates of O2●-/H2O2 production in state 2 and 4 respiration, and both GRX2+/- and 
GRX2-/- mice showed decreased respiration when treated with FCCP. This decrease in O2●-/H2O2 
production is possibly due to changes in S-glutathionylation in the mitochondrial matrix.  
 
3.3. Mitochondrial respiration 
 The bioenergetics of isolated mitochondrial samples was assessed for the liver and cardiac 
tissue to look for any changes in respiration caused by GRX2 deficiency, as well as to ensure that 
the mitochondria remained functional after isolation. In liver tissue, GRX2+/- mice showed 
significant increases in both state 2 and 3 respiration (Fig. 3.15A) However, in cardiac tissue there 
was a significant decrease in state 3 respiration for both GRX2+/- and GRX2-/- mice (Fig. 3.15B). 
This decrease in state 3 respiration in cardiac mitochondria deficient in GRX2 was observed in a 
previous study (117), and is likely due to increased S-glutathionylation of complex I. The loss of 
GRX2, leading to increased complex I S-glutathionylation, likely decreases the activity of complex 
I, diminishing the flow of electrons through the ETC, causing reduced oxygen consumption.  
 The RCR is a measurement of the mitochondrial coupling state. Typical RCR values vary 
from 3 to 15 (142), which indicate that the mitochondria are functional and undamaged from the 
isolation procedure. RCR values for each genotype in cardiac tissue were measured and found to  
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Figure 3.15: Changes in respiratory states due to loss of GRX2 
(A) The oxygen consumption of 0.5 mg/ml of liver mitochondria from each genotype was 
measured with a clarke electrode. All rates were normalized to the rate of oxygen consumption 
with the addition of 4 μM antimycin A. (B) The oxygen consumption was measured under the 
same conditions with 0.1-0.2 mg/ml of cardiac mitochondria from each genotype. N=4, mean + 
SEM, one-way ANOVA with a Fischer’s LSD post-hoc test.  
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be consistently approximately 3, indicating the mitochondria were functioning properly (Fig. 
3.16). In the liver tissue, WT and GRX2+/- mice had consistent RCR values, however, GRX2-/- 
mice had a significantly increased RCR, almost twice as large as WT mice (Fig. 3.16). This may 
indicate that the loss of GRX2 in liver tissue causes increased mitochondrial coupling, due to 
decreases in proton leak. This may be due to changes in the S-glutathionylation profile of the 
mitochondria.  
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Figure 3.16: Deregulated S-glutathionylation in the liver may lead to decreased proton leak 
The RCR of mitochondria from each genotype was measured as the ratio of state 3: state 4 
respiration. RCR values were compared within tissues. N=4, mean + SEM, one-way ANOVA 
with a Fischer’s LSD post-hoc test.   
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4. Discussion 
4.1. Summary 
 The purpose of this investigation was to examine the role of the thiol oxidoreductase GRX2 
in the regulation of O2●-/H2O2 production from various sites in liver and cardiac mitochondria. 
Using mice deficient for GRX2, mitochondria isolated from liver and cardiac tissue were examined 
for rates of O2●-/H2O2 production using various substrate and inhibitor combinations. It was 
initially found that the major sources of O2●-/H2O2 production differ between cardiac and liver 
mitochondria. In liver mitochondria, the major sources of O2●-/H2O2 included Krebs cycle enzyme 
OGDH and complex III of the ETC. Meanwhile, in cardiac mitochondria, complexes I and III of 
the ETC served as the high capacity sites for ROS release. It was also found that GRX2 deficiency 
affected O2●-/H2O2 production differently in liver and cardiac mitochondria. Most of the GRX2 
deficiency effects were associated with decreased O2●-/H2O2 release from OGDH and PDH in liver 
mitochondria. By contrast, in cardiac mitochondria, the absence of GRX2 significantly augmented 
succinate induced O2●-/H2O2 production by the ETC. 
 Measurement of the rate of O2●-/H2O2 production in liver mitochondria with different 
substrates allowed for the identification of the high capacity sites for ROS production in this tissue. 
Pyruvate or 2-oxoglutarate were excellent substrates for O2●-/H2O2 production, while 
supplementation with succinate induced low rates of O2●-/H2O2 production. Inhibition of OGDH 
with KMV induced a large decrease in O2●-/H2O2 production. Myxothiazol, a complex III inhibitor, 
also induced a small decrease in ROS production. These results indicate the Krebs cycle complexes 
OGDH, and likely PDH, along with complex III, are the major sources of ROS in liver 
mitochondria. The loss of GRX2 in liver mitochondria metabolizing pyruvate was found to cause 
decreased O2●-/H2O2 production. This is likely due to increased S-glutathionylation of Krebs cycle 
 93 
enzymes PDH and OGDH, which have already been shown to decrease O2●-/H2O2 production 
following S-glutathionylation of the E2 subunit (44, 61). The protein abundance of PDH and 
OGDH was also found to be increased in liver mitochondria. It is likely that chronic deregulation 
of protein S-glutathionylation reactions due to GRX2 deficiency induces mitochondrial stress 
signals to increase PDH and OGDH in an effort to maintain Krebs cycle flux.  
 Mitochondria isolated from cardiac tissue show a very different profile from that of the 
liver. When supplemented with pyruvate or 2-oxoglutarate, the rates of O2●-/H2O2 production from 
cardiac mitochondria are much lower than the liver. When metabolizing these substrates, KMV 
had little effect on O2●-/H2O2 production, and the use of myxothiazol increased ROS production. 
Rates of O2●-/H2O2 production by cardiac mitochondria oxidizing succinate on the other hand were 
~4x higher than the rate of ROS release during pyruvate or 2-oxoglutarate metabolism. Inhibition 
of the complexes in the ETC during succinate supplementation lead to drastic decreases in O2●-
/H2O2 production. All this evidence suggests that complexes I and III are the major sources of ROS 
in cardiac mitochondria. GRX2 deficiency in cardiac mitochondria had no effect on O2●-/H2O2 
production during pyruvate and 2-oxoglutarate oxidation. However, cardiac mitochondria from 
GRX2+/- or GRX2-/- mice displayed a significant increase O2●-/H2O2 production when succinate 
was being metabolized. This may be caused by increased S-glutathionylation of complex I in 
cardiac mitochondria, which has previously been shown to lead to increased O2●-/H2O2 production 
from the complex (121). GRX2 deficiency also leads to decreased state 3 respiration in cardiac 
mitochondria, as S-glutathionylation of complex I has been shown to decrease its activity (117, 
123).  
 The combined results of this study indicate that GRX2 plays an important role in regulating 
the production of O2●-/H2O2 in mitochondria by altering the S-glutathionylation profile. The effects 
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of GRX2 and S-glutathionylation on ROS production are different between cardiac and liver 
tissue, as the amount of ROS emitted from mitochondrial sites of production differs between the 
two tissues.  
4.2. Importance of GRX2 in health and development 
4.2.1. GRX2 is required to regulate cell metabolism and survival 
 The role of GRX2 in cellular models has been thoroughly examined to determine its 
significance in maintaining mitochondrial function. GRX2 has been found to have a protective 
effect in HeLa cells when challenged with doxorubicin, an anti-cancer drug which is known to 
increase the production of ROS (112). Silencing GRX2 expression via short inferring RNA, led to 
the dramatic sensitization of HeLa cells to cell death by doxorubicin treatment, decreasing the 
median effective dosage from 40 M to 0.7 M (112). These results suggest that the presence of 
GRX2 is required to restore the redox status of one or more targets in the mitochondria, preventing 
cell death during increased levels of oxidative stress (112).  
 The function of GRX2 in protecting cells from cell death through prevention of oxidative 
stress has been also been examined in cells overexpressing GRX2. Overexpression of GRX2 in 
HeLa cells was found to decrease susceptibility to apoptosis following doxorubicin treatment 
(118). Indeed, GRX2 overexpression inhibited cytochrome c release, preventing the induction of 
intrinsic apoptotic signaling cascades (118). Increased expression of GRX2 was found to prevent 
the doxorubicin-mediated loss of cardiolipin, the lipid which anchors cytochrome c to the 
mitochondrial inner membrane (118). Other studies suggest that the ability of GRX2 to prevent 
apoptosis induced by oxidative stress lies in its ability to preserve the function of complex I. Wu 
et al. (143) found that in human epithelial lens cells, that GRX2 protected cells from H2O2 
mediated apoptosis, which correlated with increased complex I activity. By contrast, in GRX2 
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knock down cells, the activity of complex I was significantly diminished following a H2O2 
challenge (143). Using primary cell culture of epithelial lens cells collected from GRX2 knock out 
mice, further proof was found that GRX2 protects complex I function (135). Treating these cells 
with H2O2 showed that the loss of GRX2 induces mitochondrial inner membrane leakage, 
decreased complex I activity and ATP production, and a weakened ability to detoxify H2O2 (135). 
Results from this thesis agree with these findings, as the loss of GRX2 was found to increase the 
production of ROS from complex I in cardiac cells, likely due to increased S-glutathionylation of 
the complex.  
 Cellular studies have also been used to examine the function of GRX2 in protection against 
disease. GRX2 has been studied for its role in neuronal dopamine-induced apoptosis, a 
phenomenon seen in neurodegenerative diseases, such as Parkinson’s disease. Using a primary 
culture of granule neurons from BALB/c mice, the overexpression of GRX2 was found to reduce 
dopamine induced apoptosis by stabilizing nuclear factor NF-B, which resulted in the expression 
of genes related to the immune response, stress, inflammation, and the inhibition of apoptosis 
(144). This was mediated by GRX2 induced expression of Ref-1, a redox controlled factor that 
activates NF-B (144). The ability of GRX2 to maintain a reduced mitochondrial matrix may also 
be important in the prevention of amyotrophic lateral sclerosis. The overexpression of GRX2 in 
both murine and human neuronal cell lines has been shown to prevent the aggregation of mutant 
SOD1 in mitochondria (145). Mutant SOD1 has been suggested as a possible cause for the 
degeneration of motor neurons, and its aggregation results in the impairment of oxidative 
phosphorylation (145). Finally, GRX2 has also been found to protect oligodendrocytes from 
nitrosative stress by scavenging nitric oxide (146).The role of GRX2 in maintaining functionality 
in the mitochondrial matrix has been linked to the prevention of many cellular dysfunctions. The 
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evidence discussed above is indicative of the importance of GRX2 and S-glutathionylation in the 
mitochondria. It is possible that GRX2 plays a major role in healthy cellular function and its loss 
can be detrimental. Exploring the mechanisms by which GRX2 exerts its control may lead to 
further understanding of certain diseases.  
4.2.2. Understanding the physiological function of GRX2 using mouse models  
 GRX2 is required to protect from oxidative stress and maintain mitochondrial function 
through reversible S-glutathionylation reactions. To understand its physiological function, 
transgenic animals either deficient or overexpressing GRX2 have been utilized in a number of 
studies. Most of this work has focused on the function of GRX2 in regulating cardiac physiology 
and protecting heart tissue from oxidative stress. For instance, it was found that the overexpression 
of GRX2 protected cardiac tissue from doxorubicin-induced heart damage by preserving 
mitochondrial respiration, ATP production, and preventing the release of pro-apoptotic factors 
from the intermembrane space of mitochondria (111). Mice with increased GRX2 expression were 
also protected from a decline in left ventricular function and damage to cardiac tissue (111). 
Treatment of GRX2 transgenic mice with iBid, an inducer of apoptosis, also showed decreased 
release of cardiolipin when compared to WT mice (111). This indicates that regulation of protein 
S-glutathionylation in cardiac tissue is essential for maintaining its physiological function. In the 
present study, it was demonstrated that GRX2 deficiency augments succinate-induced ROS 
production which is associated with a substantial decrease in phosphorylating respiration. Cardiac 
tissue relies heavily on a steady supply of ATP to maintain its hemodynamic function. In addition, 
cardiomyocytes are quite vulnerable to the over production of ROS which can lead to oxidative 
stress and damage. Therefore, it is likely that the absence of GRX2 results in cardiac dysfunction 
by compromising the delivery of ATP while simultaneously exposing healthy heart cells to high 
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ROS levels. These effects are likely associated with the inability of GRX2 to catalyze reversible 
S-glutathionylation reactions.  
  The results from this thesis indicate that GRX2 is required for the regulation of ROS 
production in mitochondria. Many previous studies have highlighted the importance of GRX2 in 
maintaining proper health and development. Mice with a whole body GRX2 knock out have been 
extensively profiled and found to show certain detrimental characteristics. In a previous study, 
GRX2-/-  mice were found to display a slight decrease in body weight when compared to their WT 
littermates (134). This was related to deregulated proton leaks in skeletal muscle mitochondria 
which resulted in increased overall mitochondrial respiration and carbon catabolism (134). It needs 
to be emphasized though that GRX2 deficient mice do not display any changes in linear growth or 
food intake in comparison to WT litter mates (134). GRX2 deficient mice were also found to have 
significantly heavier hearts than WT mice (117). Upon closer examination, GRX2-/- mouse hearts 
were found to display left ventricular hypertrophy and fibrosis by 9 weeks of age (117). It was also 
found that left ventricular hypertrophy developed as early as 6 weeks of age, which was not 
associated with an increase in hypertension (117). In the same study, it was also found that hearts 
from GRX2-/- mice rely heavily on glucose as a source of ATP indicating that mice develop 
metabolic inflexibility which is normally associated with mitochondrial dysfunction, a hallmark 
of cardiac disease (117). At the molecular level, GRX2 deficient mice were found to have a lower 
GSH/GSSG ratio than WT mice, which was associated with an increase in the total number of S-
glutathionylated proteins (117). In the present study, it was also found that GRX2 knockout leads 
to hyper-glutathionylation of the mitochondrial proteome in cardiac and liver tissue (134, 135). In 
addition, a previous report showed that elimination of GRX2 induces mitochondrial fragmentation 
and alterations in the expression of the respiratory complexes, including complex I, and the 
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availability of cytochrome c (117). GRX2 is well known to target complex I in cardiac tissue for 
regulation by reversible S-glutathionylation (121). Without GRX2 present to regulate S-
glutathionylation reactions, increased S-glutathionylation of complex I causes significant increases 
in ROS production (121). Since complex I is an integral source of O2●-/H2O2 in cardiac 
mitochondria, deregulation of its S-glutathionylation due to a loss in GRX2 function is the likely 
cause for oxidative damage to cardiac tissue. In this thesis, cardiac mitochondria from GRX2-/- 
mice displayed decreased state 3 respiration, an observation that is consistent with other reports 
showing GRX2 and protein S-glutathionylation are vital for regulating complex I activity and 
mitochondrial respiration. This change in mitochondrial respiration has been previously noted, and 
further research has also found that GRX2-/- mice have decreased ATP production (117). 
Modulation of mitochondrial bioenergetics in cardiac tissue, causing increased ROS production 
and decreased oxidative phosphorylation efficiency, are likely the cause of the ventricular 
hypertrophy and hypertension noted in these mice. This evidence indicates that the presence of 
GRX2 is required for normal cardiac function, as S-glutathionylation reactions must be regulated 
in the mitochondria to prevent unwanted changes in mitochondrial physiology.  
 The loss of GRX2 expression in the mouse model has not been found to cause any 
subsequent upregulation of related enzymes in the oxidoreductase family. This study, as well as 
others (113), found no compensatory increase in GRX1. This is expected since GRX1 resides in 
the mitochondrial intermembrane space and thus would not be able to compensate for a loss in 
GRX2 function. Another more likely candidate for GRX2 compensation would be TRX2, a 
member of the thioredoxin-fold family that has been implicated in driving S-glutathionylation 
reactions. However, it has also been shown that the loss of GRX2 does not lead to compensatory 
increases in TRX1 or TRX2 in mitochondria isolated from lens, muscle, or cardiac tissue (117, 
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134, 135). It should be noted though that several studies have documented that TRX2 does not 
catalyze S-glutathionylation since it lacks the GSH motif required to remove GSH from a target 
protein (147). It is possible that the loss of GRX2 may lead to regulation of S-glutathionylation 
reactions by GST. Isoforms of GST are present in the mitochondrial matrix (148), but little is 
known about whether these enzymes have the ability to perform reversible S-glutathionylation 
reactions in the matrix of mitochondria.  
 A GRX2 whole body knock out model has also been used in the study of cataract formation. 
Previous studies in mouse epithelial lens cells have indicated that GRX2 is required to maintain 
the functionality of complex I during oxidative stress, preserving mitochondrial oxidative 
phosphorylation (135). Compared to WT mice, GRX2-/- mice were shown to induce the formation 
of age-related cataract development approximately three months sooner (113). The lenses of the 
GRX2 null mice contained lower levels of protein thiols and GSH than WT mouse lenses, with a 
significant increase in S-glutathionylation proteins (113). The inappropriate addition of GSH to 
proteins may lead to protein destabilization, and the eventual formation of water-insoluble protein 
aggregates that cause clouding of the lens (113). The mitochondrial function in the lenses of GRX2 
null mice was also affected. Mitochondrial preparations from the GRX2 null lens showed 
decreased complex I activity as well as decreased overall ATP production (113). These results 
indicate that multiple tissues require the activity of GRX2 to maintain properly functioning 
mitochondria, and to allow the tissue to perform its physiological function.  
4.2.3. The role of GRX2 in embryogenesis 
 In addition to its role in maintaining mitochondrial function, GRX2 has also been shown 
to be required for proper embryonic development. GRX2 has been implicated in the cardiac, 
vascular and brain development. In the zebrafish model, GRX2 has been found to be necessary for 
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the migrations of cardiac neural crest cells into the primary heart field (116). The knockdown of 
GRX2 led to impaired migration of these cells, causing obstructed blood flow and reduced 
pumping efficacy due to disrupted looping of the cardiac tube (116). It was suggested that this 
impairment is caused by disruptions in the reversible S-glutathionylation of actin by GRX2 (116).  
GRX2 deficiency also causes delayed and disordered blood vessel network development (115). 
Investigation of this phenomenon led to the discovery that for proper blood vessel development, 
the presence of GRX2 is required for the deglutathionylation of a certain cysteine residue on 
NAD+-dependant protein deacetylase sirtuin-1 (115). This mechanism was also confirmed in HeLa 
cells, demonstrating that it is applicable to humans as well as zebrafish. Lastly, the role of GRX2 
was also studied in zebrafish brain development. Silencing the expression of GRX2 in a zebrafish 
model led to increased apoptosisin neurons, as well as the loss of the ability to develop an axonal 
scaffold (114). In a zebrafish and human cell model, it was demonstrated that GRX2 is required 
for the thiol redox regulation of collapsin response mediator protein 2, which is needed for axon 
growth guidance (114). These studies further highlight the important role of GRX2 in numerous 
thiol redox reactions that are required throughout the body for health and development.  
4.3. Production of O2●-/H2O2 during pyruvate/2-oxoglutarate oxidation  
4.3.1. Liver mitochondria metabolizing pyruvate/2-oxoglutarate 
 The results of this thesis indicate that the majority of O2●-/H2O2 produced in liver 
mitochondria comes OGDH of the Krebs cycle and complex III of the ETC. PDH is also an 
important source but produces less ROS than OGDH and complex III. Previous studies examining 
the main sources of ROS production in liver mitochondria agree with these findings. Findings by 
Slade et al. (62) showed that while complex III is the main source of O2●-/H2O2 production, OGDH 
also produces a significant amount. Complexes I and III are traditionally viewed as the main 
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sources of ROS production in mitochondria (86). However, identification of PDH and OGDH as 
important sources of mitochondrial O2●-/H2O2 has challenged this view. Indeed, PDH and OGDH 
have been found to be important sources of ROS production in liver, muscle, and brain 
mitochondria (44, 128). In fact, in skeletal muscle, PDH and OGDH have been found to produce 
4x and 8x more ROS than complex I during the oxidation of Krebs cycle-linked substrates (128). 
Although PDH and OGDH have analogous structures, their ROS production potentials are not 
equal. In skeletal muscle, PDH is found to produce about half as much ROS as OGDH (128). In 
liver mitochondria, OGDH accounts for ~35% of the ROS emission whereas PDH produces ~7% 
of the total amount of O2●-/H2O2 (62). In this thesis, the inhibition of OGDH with KMV in liver 
mitochondria led to a ~85% decrease in O2●-/H2O2 production when pyruvate or 2-oxoglutarate 
served as the substrate. It is important to emphasize that malate was also included in the reaction 
mixtures to complete the Krebs cycle and ensure that any acetyl-CoA formed by PDH can be 
condensed with oxaloacetate allowing for further oxidation. Therefore, as in previous studies, 
OGDH is a far more significant source for O2●-/H2O2 than PDH.  
 Mitochondrial O2●-/H2O2 production depends on the concentration and redox state of the 
electron donating site. Both OGDH and PDH were also more abundant in liver mitochondria 
isolated from GRX2-/- mice. Therefore, we decided to normalize the amount of O2●-/H2O2 
production to the abundance of each complex since the overall concentration of both enzymes will 
influence the rate of ROS release. Normalizing the results to overall PDH and OGDH content 
revealed that a deficiency in GRX2 results in a significant decrease in O2●-/H2O2 production. It is 
likely that this is associated with the increased S-glutathionylation of OGDH and PDH, since it 
has been established in two previous studies that GRX2 is required to deglutathionylate both 
enzymes (44, 61). The compensatory increase in PDH and OGDH protein abundance is either 
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related to mitochondrial stress signaling to the nucleus or an increase in mitochondrial 
proliferation.  
 It was shown nearly a decade ago that OGDH can be S-glutathionylated on the lipoic acid 
site of its E2 subunit (130). This S-glutathionylation was found to occur when mitochondria were 
challenged with high levels of H2O2 (130). Hydrogen peroxide has a high activation energy which 
prevents it from spontaneously oxidizing most protein cysteine thiols. However, at high enough 
concentrations, H2O2 can oxidize protein cysteine thiols forming highly nucleophilic SOH. 
Sulfenic acid is very unstable and can undergo a range of modifications – during oxidative stress 
sulfenic acids can either be irreversibly oxidized by H2O2 further or can be covalently modified by 
lipid peroxidation degradation products like 4-HNE (99). The vicinal thiols on the lipoic acid of 
the E2 subunit in OGDH and PDH are highly sensitive oxidative deactivation by H2O2 (22). 
Moreover, oxidative deactivation of OGDH occurs in several neurological and metabolic disorders 
(99). S-glutathionylation of OGDH is required to protect the enzyme complex from irreversible 
oxidative deactivation (130). In addition, the GSH moiety can be removed by the action of GRX2 
(22). On top of this protective function of S-glutathionylation, recent work by our group has found 
that this redox sensitive modification can also regulate ROS emission from OGDH. OGDH has 
been shown to alter its production of O2●-/H2O2 depending on its state of S-glutathionylation (132). 
S-glutathionylation of the lipoic acid residues of OGDH leads to decreased production of O2●-
/H2O2 during forward electron flow, as GSH blocks the flow of electrons from the oxidation of 2-
oxoglutarate, to the E3 subunit, where O2●-/H2O2 is produced by the flavin site (132). Based on 
this, it seems likely that the loss of GRX2 leads to hyperglutathionylation of matrix proteome, 
including the S-glutathionylation of OGDH, decreasing its production of O2●-/H2O2. Since OGDH 
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is a major source of ROS in liver mitochondria, this change causes a large decrease in the overall 
production of O2●-/H2O2.  
 Fisher-Wellman et al. showed in two studies that depletion of mitochondrial GSH or 
NADPH augments O2●-/H2O2 production by PDH (127). It was hypothesized that this regulation 
may actually occur through the S-glutathionylation of PDH (127). However, in the same study, 
the authors used GSH depleting agents to study ROS production by PDH and were thus unable to 
determine if the change in O2●-/H2O2 production was related to the depletion of a critical 
antioxidant, GSH, or via redox sensing by PDH. Our group provided the first evidence that PDH 
can undergo S-glutathionylation, an observation that should not be surprising given that PDH is 
highly homologous to OGDH (61). S-glutathionylation of PDH also lowers the production of O2●-
/H2O2 in the forward electron transfer (61). Moreover, in the same study it was found that GRX2 
can remove GSH from PDH. Therefore, it is likely that the loss of GRX2 also induces the S-
glutathionylation of PDH, decreasing its O2●-/H2O2 production and contributing to the overall 
decrease of ROS production in the mitochondria. However, as PDH is a less significant source of 
O2●-/H2O2 than OGDH in liver tissue (44), it is likely that its inhibition has a lesser effect on the 
overall ROS production as compared to the S-glutathionylation of OGDH. The loss of GRX2 is 
likely to affect the S-glutathionylation status of both OGDH and PDH, as both complexes have 
been shown to be deglutathionylated by GRX2 (61, 132).  
4.3.2. Cardiac mitochondria metabolizing pyruvate/2-oxoglutarate 
 The results of this experiment indicate that both pyruvate and 2-oxoglutarate are poor 
substrates for inducing O2●-/H2O2 production in isolated cardiac mitochondria. Utilization of either 
of these substrates induced O2●-/H2O2 production rates approximately 5x lower than in liver 
mitochondria. This indicates that OGDH and PDH are not likely to be important sources of O2●-
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/H2O2 production in cardiac mitochondria. A previous study by the Mailloux group (44) also found 
that liver mitochondria generated approximately ~3-4.5x more ROS than cardiac mitochondria, in 
the presence of either pyruvate or 2-oxoglutarate. Since the Krebs cycle is not found to be an 
important source of ROS in cardiac mitochondria, inhibition of OGDH with KMV did not lead to 
a decrease in O2●-/H2O2 production. The inhibition of complex III with myxothiazol led to an 
increase in O2●-/H2O2 production. This indicates that complexes upstream of complex III may be 
important sites of ROS production, such as complexes I and II. Myxothiazol binds to the UQH2 
binding site of complex III, preventing the complex from accepting electrons. This leads to reverse 
electron transfer to complexes I and II, indicating a significant amount of ROS is being produced 
from either of these sites.  
 The loss of GRX2 in cardiac mitochondria did not lead to any significant change in O2●-
/H2O2 production during supplementation with pyruvate or 2-oxoglutarate. Unlike liver 
mitochondria, there was also no changes in OGDH and PDH abundance between WT and GRX2 
deficient mice. Therefore, we did not normalize O2●-/H2O2   production rates to enzyme content in 
this tissue. It’s possible that increased S-glutathionylation of Krebs cycle complexes does not have 
a very noticeable effect on overall ROS production rates in cardiac mitochondria, as they do not 
produce significant amounts of ROS in this tissue.  
4.4. Production of O2●-/H2O2 during succinate supplementation 
4.4.1. Liver mitochondria metabolizing succinate 
 The supplementation of isolated liver mitochondria with succinate was determined not to 
be an effective method of inducing O2●-/H2O2 production. The rates of O2●-/H2O2 production in 
liver mitochondria were about ~3x lower in comparison to pyruvate or 2-oxoglutarate. This data 
supports the previously discussed notion that enzyme complexes PDH and OGDH are important 
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sources of O2●-/H2O2 production in liver mitochondria. Electrons from succinate are passed to UQ 
via complex II of the ETC, therefore bypassing both PDH and OGDH, eliminating their ability to 
produce O2●-/H2O2. Since the supplementation with succinate led to a significant decrease in O2●-
/H2O2 production, we can deduce that complexes I and II are not significant sources of O2●-/H2O2 
in liver mitochondria. It is likely that the O2●-/H2O2 being produced with succinate 
supplementation is from complex III, which has previously been discussed to be a significant O2●-
/H2O2 source in liver mitochondria (62). The use of ETC inhibitors in liver mitochondria 
supplemented with succinate also provides data which supports these conclusions. Mxyothiazol, 
an inhibitor of the UQH2 binding site of complex III, induced a small decrease in O2●-/H2O2 
production. Both atpenin A5, a complex II UQ inhibitor, and rotenone, a complex I UQ inhibitor, 
did not alter the rate of O2●-/H2O2 production in WT mice. These results indicate that when liver 
mitochondria are metabolizing succinate, complex III may be a significant source of O2●-/H2O2 
production, while both complexes I and II are not.  
 We also noted a significant increase in O2●-/H2O2 production in GRX2+/- mouse liver tissue, 
as compared to WT, during succinate supplementation. This is possibly due to increased S-
glutathionylation of complex I, which has been shown to lead to increased production of O2●-/H2O2 
(121). While complex I was not found in the liver to be a significant source of O2●-/H2O2 in the 
liver, it’s possible that increased S-glutathionylation induced increased rates of O2●-/H2O2 
production during reverse electron flow from complex II. Previous research with GRX2 deficient 
mice has shown that they present with increased S-glutathionylation of complex I, leading to 
decreased activity (117). It is possible that since succinate results in such low rates of ROS 
production in the liver mitochondria, that it is difficult to know if the increase seen in heterozygotes 
is truly significant, or if it is based in error. A larger n value could fix this problem. However, it is 
 106 
also possible that there is a compensatory response occurring in the GRX2 KO mice preventing 
the increase of ROS production, which is not present in the heterozygous mice.  
4.4.2. Cardiac mitochondria metabolizing succinate 
 Cardiac mitochondria supplemented with succinate showed a robust increase in O2●-/H2O2 
production as compared to pyruvate or 2-oxoglutarate. These results indicate that succinate is an 
effective stimulator of O2●-/H2O2 production in cardiac mitochondria. This is likely because sites 
of ROS production in the ETC have been found to be more significant sources of O2●-/H2O2 
production in cardiac mitochondria when compared to sites in the Krebs cycle. Since succinate 
enters the ETC at complex II, it is able to stimulate O2●-/H2O2 production from complexes II and 
III, as well as by complex I via reverse electron transport by UQH2. Inhibitors of ETC complexes 
were also used in cardiac mitochondria to pinpoint sites of O2●-/H2O2 production. All three 
inhibitors: rotenone, atpenin A5, and mxyothiazol, had a noticeable effect, inducing large 
decreases in the rates of O2●-/H2O2 production. Interpretation of these results lead to the conclusion 
that complexes I and III are significant sources of O2●-/H2O2 production in cardiac mitochondria, 
as blocking electron transfer to these sites led to large decreases in overall O2●-/H2O2 production. 
Complex II was found not to be a significant source of O2●-/H2O2 production in cardiac tissue, as 
blocking electron flow out of the complex by atpenin A5 led to a decrease in O2●-/H2O2 production, 
whereas an increase would be expected if complex II was a major site of O2●-/H2O2 production. 
Previous research in brain mitochondria has shown similar results, with complexes I and III being 
the major sites of ROS production (149). Combined with the results from this thesis, it appears 
that tissues with high-oxygen requirements, such as brain and cardiac tissue, rely heavily on 
complexes I and III for ROS production.  As complex I is known to be an important site in the 
mitochondria for regulation of ROS production (117, 121, 123), this likely allows high-oxygen 
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tissues to control their ROS production and oxidative phosphorylation efficiency by altering the 
glutathionylation state of complex I.  
 GRX2 deficient mice also showed significant increases in O2●-/H2O2 production as 
compared to WT mice during succinate supplementation. Both GRX2-/- and GRX2+/- mouse 
cardiac mitochondria showed levels of O2●-/H2O2 production approximately twice as large as WT 
mice. This increase in O2●-/H2O2 due to the loss of GRX2, like in the liver tissue, is also likely due 
to increases in the S-glutathionylation status of complex I. Since complex I is a much more 
significant source of ROS in cardiac tissue, rates of O2●-/H2O2 production are very significantly 
increased when S-glutathionylated in the absence of GRX2. The increased S-glutathionylation of 
complex I is very likely in GRX2 deficient mice as they showed decreased state 3 respiration, 
likely due to the decreased activity of complex I which occurs when S-glutathionylated (121). 
Recent evidence in yeast studies have indicated that complex III may also contain sites for S-
glutathionylation (140). It is possible that, like complex I, increased S-glutathionylation of 
complex III may increase O2●-/H2O2 production, however this is only speculative as no studies 
have yet examined S-glutathionylation of complex III in mammals and its effects on ROS 
production.  
4.5. Proton gradient on O2●-/H2O2 production 
 The theory that mild uncoupling of mitochondria may reduce ROS induced damage has 
been widely examined, and still there is much debate about the veracity of this hypothesis. In this 
study, there seemed to be no correlation between the proton gradient and the rate of O2●-/H2O2 
production in liver or cardiac tissue. The addition of FCCP, which dissipates the mitochondrial 
membrane potential, led to an increase in O2●-/H2O2 production in both tissues. This contrasts with 
the theory that decreases in membrane potential should lead to reduced ROS production.  However, 
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there is much evidence that does not support this theory. Previous research has indicated that ROS 
production from complex I-linked substrates is not sensitive to decreases in the proton gradient 
mediated by chemical uncouplers in liver or heart tissue (150). However, some studies have found 
a correlation (76). The evidence for the regulation of ROS production by mild uncoupling through 
UCP 1/2/3 has been widely disputed (151). Therefore, the results obtained in this study support 
the emerging theory that membrane potential does not play a role in controlling the amount of 
ROS produced in the mitochondria. 
4.6. Conclusions 
The present study demonstrates that protein S-glutathionylation reactions mediated by GRX2 
are integral for the regulation of mitochondrial O2●-/H2O2 production. In addition, the evidence 
presented herein indicates that S-glutathionylation reactions target different enzymes in different 
tissues. For example, GRX2 deficiency decreased pyruvate and 2-oxoglutarate driven O2●-/H2O2 
release in liver, an effect that was absent in cardiac mitochondria. This indicates that PDH and 
OGDH are targets for regulation by GRX2 in liver mitochondria. By contrast, GRX2 deletion 
augmented succinate driven ROS production in cardiac mitochondria, which is most likely related 
to the S-glutathionylation of complex I. Therefore, we can surmise that GRX2 targets high capacity 
sites of ROS production for regulation by S-glutathionylation. Loss of this function compromises 
the regulation of mitochondrial O2●-/H2O2 production which can either limit mitochondrial ROS 
signaling or induce oxidative stress due to over production. In aggregate, the results collected in 
this study illustrate that redox signals are vital for regulating mitochondrial O2●-/H2O2 production. 
Based on this, we hypothesize that mitochondrial S-glutathionylation reactions are required to 
regulate mitochondrial ROS signaling. Furthermore, our results demonstrate that GRX2-mediated 
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S-glutathionylation reactions target different enzymes in different tissues to properly modulate 
ROS production.  
4.7. Future Directions 
Based upon the results obtained in this thesis, future directions for this work will include: 
1. Challenging the GRX2 deficient mice with a high fat diet and examining changes in 
ROS production as compared to WT mice 
2. Cardiac ischemia reperfusion modelling and doxorubicin challenging of GRX2 
deficient cardiac mitochondria 
3. Investigation of how S-glutathionylation reactions modulate the production of 
mitochondrial ROS in skeletal muscle 
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